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1. Introduction 
1.1 Pancreatic ductal adenocarcinoma (PDAC) 
1.1.1 Clinical and pathological aspects of PDAC 
The pancreas is a central organ in the digestive system with an exocrine function that 
comprises secretion of digestive enzymes and an endocrine function that controls the 
blood sugar level. Most neoplasms in the pancreas develop from ductal or acinar cells 
of the exocrine part and are called pancreatic ductal adenocarcinoma (PDAC). In the 
Western world, PDAC is the fourth-leading cause of cancer-associated death and the 
five year survival rate is only eight percent [1]. The global burden of PDAC is expected 
to increase in the next decade and it is estimated that PDAC will be the second-leading 
cause of cancer death in 2030 [2]. Recent modeling confirmed this estimation for 
Germany [3]. One reason for the poor prognosis is the late time of diagnosis, when most 
of the primary tumors (> 80%) have already metastasized regionally or distantly [4]. 
Patients with distant metastasis have the worst prognosis with a five-year survival rate 
of three percent [1] and a median survival of 3-4 months [5].  
 
Smoking, excessive alcohol consumption, overweight and chronic pancreatitis are 
known risk factors for PDAC [6, 7]. A small proportion of pancreatic cancer patients have 
elevated inherited risk due to a germline mutation of the DNA damage repair components 
Breast Cancer 1, early-onset (BRCA1) and BRCA2 [8]. Under inflammatory or stress 
conditions, acinar cells of the exocrine pancreas transdifferentiate into ductal-like cells 
and acquire progenitor-like characteristics in a process called acinar-to-ductal 
metaplasia (ACM). Those highly plastic cells are prone to develop into tumors if they 
acquire additional oncogenic hits. Over 90% of PDAC patients acquire activating 
mutations in the proto-oncogene KRAS. Furthermore, the KRAS locus is frequently 
amplified, which was recently associated with early tumor development and metastasis 
[9]. In addition to the activation of the proto-oncogene KRAS, several tumor suppressors 
including TP53, cyclin dependent kinase inhibitor 2A (CDKN2A) and MAD-Homolog 4 
(SMAD4) are frequently inactivated in patients with pancreatic cancer.  
 
Several whole genome and transcriptome sequencing approaches have defined four 
distinct subgroups of pancreatic cancer: 1) squamous subtype, 2) aberrantly 
differentiated endocrine/exocrine (ADEX) subtype, 3) pancreatic progenitor subtype, and 
4) immunogenic subtype [10-12]. Recent studies confirmed this classification and 
Introduction 2 
 
defined histological markers such as keratin 81 (KRT81) and hepatocyte nuclear factor 
1A (HNF1A) for routine classification of patients with pancreatic cancer [13]. 
 
1.1.2 Tumor microenvironment of PDAC 
The tumor microenvironment of PDAC is characterized by dense infiltration of various 
non-neoplastic cells including pancreatic stellate cells (PSC), cancer-associated 
fibroblasts (CAF) and immune cells. Already early in tumorigenesis, there is a close 
cross-talk between transformed pancreatic cells and surrounding bystander cells. During 
inflammation, PSC are pathologically activated and produce large amounts of 
extracellular matrix (ECM) deposits [14]. Recent data suggest that focal adhesion kinase 
1 (FAK1) activity of early transformed neoplastic cells mediates the stromal-rich 
microenvironment and FAK1 inhibition leads to stromal remodeling [15]. High stromal 
content is described to be one driver of therapy resistance. Stromal matrix stiffness 
reduces drug delivery and stromal cells have been described to increase the pro-
inflammatory cytokine milieu [16] .  
 
Other key components of the tumor microenvironment in PDAC are immune cells such 
as macrophages, monocytes and granulocytes. Macrophages are polarized into a M2 
pro-tumoral and pro-angiogenic state. Tumor-associated M2 macrophages (TAM) 
suppress T cell responses against tumor cells and increase the tumor-initiating capability 
of pancreatic tumor cells by activating tumor intrinsic signal transducer and activator of 
transcription 3 (STAT3) signaling. Furthermore, high macrophage and low CD8+ T cell 
infiltration as well as high STAT3 phosphorylation correlates with a poor prognosis in 
patients with pancreatic cancer [17]. Monocytes and granulocytes are frequently 
enriched and exhibit immunosuppressive functions. The pathological activation of those 
cells changes their function. Therefore, such monocytes are called monocytic myeloid-
derived suppressor cells (M-MDSC) and granulocytes are called polymorphonuclear 
MDSC (PMN-MDSC) [18]. Tumor-derived CC-chemokine ligand 2 (CCL2) and CXC-
chemokine ligand 1 (CXCL1) recruit M-MDSC and PMN-MDSC into the tumor 
microenvironment, respectively [19]. In mouse studies, it has been shown that individual 
CXCL1-secreting tumor cells are capable of recruiting PMN-MDSC and thereby creating 
an immunosuppressive microenvironment which is characterized by low T cell infiltration 
and impaired T cell function [20]. In mouse models, antibody-mediated depletion of PMN-
MDSC increased the frequency of intratumoral T cell and induced tumor cell apoptosis 
[21].  
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1.1.3 Current therapy of PDAC 
In contrast to other tumor entities, the survival of patients suffering from PDAC has not 
been considerably improved over the last decades. The standard treatment for 
resectable PDAC is surgery followed by chemotherapy. Patients with locally advanced 
or metastasized PDAC are treated with chemotherapy or in some cases with 
radiochemotherapy [22]. New, very aggressive poly-chemotherapy regimens such as 
folinic acid, 5-FU, irinotecan plus oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-
paclitaxel have been recently introduced and have changed the first-line treatment 
options. However, both chemotherapies improved the overall survival of PDAC patients 
by a few months only and the harsh treatment is frequently associated with dose-limiting 
toxicity [23, 24]. The FOLFIRINOX treatment can only be offered to patients with an 
excellent performance status [23]. All trials testing targeted therapy modalities including 
multikinase inhibitors and anti-angiogenic treatment strategies did not show major clinical 
benefit [25, 26]. Only the treatment with epidermal growth factor receptor (EGFR) 
inhibitor showed minor clinical improvement, which lead to the approval for patients with 
metastatic PDAC [27]. 
 
1.1.4. Immunotherapeutic approaches in PDAC 
During the last decade, immunotherapy revolutionized the treatment of many tumor 
types. Several approaches that showed clinical benefit in other cancer types have been 
tested in clinical trials for pancreatic cancer. However, no immunotherapy has been 
approved for PDAC so far. The causes for the failure in clinical trials are believed to be 
low frequency of neo-antigens due to low mutational burden and the strong immune 
suppression in the tumor microenvironment. Patients with better neo-antigen quality and 
high frequency of CD8+ T cells have prolonged survival [28, 29]. Immune checkpoint 
inhibitors such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and anti-
programmed cell death protein 1 (PD-1) antibodies have shown efficacy in melanoma 
[30], non-small cell lung cancer [31] and head and neck cancer [32] and other solid 
tumors. However, monotherapeutic approaches did not show any benefit in the majority 
of PDAC patients [33, 34]. In melanoma, high T cell infiltration and T cell activation prior 
to therapy correlate with better treatment response to checkpoint blockade. Other 
prognostic factors are currently on the horizon [35]. In contrast to melanoma, PDAC is 
poorly infiltrated by T cells [36]. A very small group (approximately 2%) of pancreatic 
cancer patients with microsatellite instability (MSI) has shown responses to anti-PD-1 
treatment [37]. In 2017, anti-PD-1 therapy was approved by the American Food and Drug 
Administration (FDA) for MSIhigh cancer patients, including patients with PDAC [38]. 
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Patients with instable microsatellites have a higher neo-antigen load and it is believed 
that this is the reason why MSIhigh tumors have a higher chance to respond to checkpoint 
blockade [39, 40].  
 
To induce tumor antigen-specific T cells, several cancer vaccination strategies using 
recombinant peptides [41], whole cell lysates [42] or vector-based vaccines [43] have 
been tested in clinical trials. Several trials demonstrated a considerable induction of 
immune responses against the vaccinated antigens. However, no significant 
improvement in survival was convincingly demonstrated to date. Another strategy to 
improve anti-tumor immunity is the treatment with a CD40 agonistic antibody, which 
activates dendritic cells (DC) and polarizes macrophages in an anti-tumoral M1 state 
[44]. Clinical trials testing CD40 agonist in combination with chemotherapy and 
checkpoint blockade are currently ongoing [45]. Studies from our group in preclinical 
models of pancreatic cancer showed that ligands for cytosolic RNA sensors, called 
retinoic acid-inducible gene I (RIG-I)-like helicases (RLH), induce an immunogenic form 
of tumor cell death and improve antigen uptake and presentation by DC [46, 47]. RIG-I 
ligands are currently tested in clinical phase I-II studies for therapy of solid tumors 
(https://clinicaltrials.gov/ct2/results?term=RGT100). Oncolytic viruses that most likely 
activate similar immune mechanisms are also currently tested in clinical trials [48]. 
 
As described above, one key hurdle in the treatment of pancreatic cancer is the 
immunosuppressive, stroma-rich microenvironment. In pre-clinical models of PDAC, the 
recruitment of suppressive PMN-MDSC or M-MDSC was reduced by blockade of CXCL2 
or CCL2 respectively [49]. Initial phase I trials showed promising results for CCL2 
blockade in combination with chemotherapy [50, 51]. One key component of the stroma 
is hyaluronic acid. Treatment with hyaluronidase, an enzyme degrading hyaluronic acid, 
in combination with chemotherapy showed clinical benefit in a phase II trial [52]. 
However, two groups using different strategies to deplete the tumor stroma in mouse 
models of PDAC questioned the pro-tumoral role of the stroma recently [53, 54]. 
 
1.1.5 Mouse models of PDAC 
To study pancreatic cancer in mice, several mouse models have been established. Mice 
have been genetically engineered by introducing genetic alterations, which are 
frequently found in human PDAC. For example, in the classical KPC model, mutated 
KrasG12D and mutated P53R172H are introduced specifically in pancreatic precursor cells 
using the Cre-lox system. KPC mice spontaneously develop multiple neoplasms 
specifically in the pancreas. Tumors from KPC mice resemble the stroma-rich histology 
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of human PDAC and KPC mice have a short median survival of approximately five 
months [55]. Many other genetically engineered mouse models (GEMM) with pancreas-
specific tumor drivers have been established. In addition, tumor cells from GEMM have 
been isolated and cell lines have been generated. Cell lines can be implanted 
subcutaneously or orthotopically in the pancreas of C57BL/6 mice. A frequently studied 
syngenic mouse model is the Panc02 model. The Panc02 cell line has been generated 
by applying the cancerogen 3-methylcholanthrene (3-MCA) to the pancreas of wild-type 
mice. Previous work from our group showed that the orthotopically transplanted KPC-
derived cell line T110299, which is used in this study, reflects more closely the histology 
of primary tumors in the KPC mouse and also of human PDAC, as compared to the 
Panc02 model [56].  
 
1.2 Myeloid-derived suppressor cells (MDSC) 
1.2.1 Origin and nomenclature of MDSC 
During the past 15 years, there is increasing evidence that myeloid cells acquire 
suppressive capacity during cancerogenesis and are functionally different compared to 
myeloid cells in healthy controls. In 2007, Gabrilovich et al. introduced the term myeloid-
derived suppressor cells (MDSC) to harmonize the research area [57]. Increased 
frequency of myeloid cells in the tumor microenvironment is associated with poor 
prognosis across most cancer types. [58]. A recent meta-analysis showed that a high 
neutrophil-to-lymphocyte ratio is a poor prognostic factor for patients with pancreatic 
cancer [59]. 
 
MDSC develop from myeloid precursors in the bone marrow. Under physiological 
conditions, myeloid cells differentiate from hematopoietic stem cells (HSC) via the 
common myeloid precursor (CMP) and the granulocyte macrophage precursor (GMP) to 
the terminally differentiated effector cells. The tumor alters the myelopoiesis and induces 
the differentiation of MDSC (Fig. 1)[60]. Two subtypes have been identified in both 
mouse and humans [61]. On the one hand, there are polymorphonuclear MDSC (PMN-
MDSC), which develop from granulocyte precursor cells. Formerly, PMN-MDSC have 
been called granulocytic MDSC (G-MDSC). However, due to fact that these cells have a 
very low number of granules, this term is misleading and the term PMN-MDSC describes 
them better. Nevertheless, the terms PMN-MDSC and G-MDSC are interchangeable 
[18]. On the other hand, there are monocytic MDSC (M-MDSC), which derive from 
monocytic precursors. PMN-MDSC are terminally differentiated, whereas M-MDSC have 
the capability to differentiate into macrophages or PMN-MDSC [61].  
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The tumor induces a chronic, systemic, mild inflammation by secreting two classes of 
factors that manipulate the myelopoiesis and lead to the development of MDSC. Firstly, 
the tumor secretes factors such as GM-CSF, G-CSF and IL-6 which induce the 
expansion of the myeloid compartment and the accelerated release of myeloid cells from 
the bone marrow into the periphery (Fig. 1). Secondly, factors such as interferon (IFN) , 
tumor necrosis factor (TNF), interleukin (IL)-1 and IL-6 are released and induce a 
pathological activation of myeloid cells [62].  
 
Figure 1: Origin of myeloid-derived suppressor cells (MDSC) 
Myeloid cells develop from the hematopoietic stem cells (HSC) via the common myeloid 
progenitor (CMP) to the granulocyte macrophage progenitor (GMP). Under physiological 
conditions GMP differentiate into granulocytes (PMN), monocytes or dendritic cells (DC). In case 
of a tumor, the myelopoiesis is altered and PMN-MDSC and M-MDSC develop from GMP. 
Adapted from Gabrilovich (2017) [60] 
 
Recently, lectin-type oxidized LDL receptor-1 (LOX1) has been identified as a marker to 
distinguish PMN-MDSC from granulocytes in humans [63]. However, in mice Lox1 is not 
associated with PMN-MDSC. To date, no marker has been identified to distinguish 
murine PMN-MDSC from granulocytes and M-MDSC from monocytes. Bronte et al. 
defined a three-step classification to define MDSC: Firstly, the myeloid compartment has 
to be expanded. Secondly, both PMN-MDSC and M-MDSC have to express the cell 
defining surface markers (assessed by flow cytometry). Thirdly, suppressive activity has 
to be demonstrated [18].  
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1.2.2 Function of MDSC 
The suppressive mechanisms of MDSC are influenced by tumor and host-derived factors 
and differ between tumor types as well as individuals. One important mechanism is the 
depletion of the essential amino acids arginine and tryptophan by arginase 1 (ARG1) 
and indoleamine 2,3-dioxygenase 1 (IDO1), respectively. Amino acid deprivation 
induces T cell proliferation arrest and apoptosis [64]. Furthermore, MDSC secrete 
immunosuppressive cytokines, such as transforming growth factor (TGF)- and IL-10, 
which lead to the induction of regulatory T cells, M2 polarization of macrophages and 
inhibition of NK cells [65]. MDSC express inducible nitric oxide synthases (iNOS) and 
nicotinamide adenine dinucleotide phosphate oxidase (NOX), which catalyze the 
generation of reactive oxygen species (ROS) and nitrogen species (NOS). ROS and 
NOS nitrosylate the T cell receptor leading to proliferation arrest and T cell dysfunction 
[66]. Furthermore, MDSC secrete chemokines that attract other immunosuppressive 
cells [61] and express surface molecules such as PD-L1 that suppress T cells in a 
contact dependent manner [67] (Fig. 2). 
 
 
Figure 2: Suppressive mechanisms of MDSC 
MDSC suppress immune responses via distinct mechanisms: Firstly, enzymes such as 
arginase 1 (ARG-1) and indoleamine 2,3-dioxygenase 1 (IDO-1) degrade essential amino acids. 
Secondly, suppressive cytokines such as IL-10 or TGF- remodel immune cells. Thirdly, reactive 
oxygen and nitrogen species (ROS and NOS) are produced inducing T cell dysfunction. Fourthly, 
immunological checkpoints such as PD-L1 are expressed, binding to T cells via PD-1 and thereby 
inhibition T cell function. Adapted from de Haas et al. (2016) [68].  
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1.3 RIG-I-like helicases (RLH) 
1.3.1 Physiological role of RLH 
Under physiological conditions, the cytoplasm of healthy cells contains only modified 
RNA (e.g. 5’-capped mRNA). Upon virus infection, unmodified viral RNA is present in the 
cytoplasm and this RNA is sensed by RNA binding proteins including retinoic acid-
inducible gene I (RIG-I) and melanoma differentiation-associated antigen 5 (MDA5). 
RIG-I and MDA5 are members of the RIG-I-like helicases (RLH) family. MDA5 
recognizes long double-stranded RNA molecules and RIG-I recognizes the 
5’-triphosphate moiety of unmodified viral RNA [69, 70]. Both receptors signal via 
mitochondrial antiviral-signaling protein (MAVS) and induce a type I IFN response and 
pro-inflammatory cytokine secretion. Thereby, virus-infected cells induce in an auto- and 
paracrine manner antiviral programs including immune activation and induction of 
antigen presentation. Depending on the viral load, RLH signaling is also capable of 
inducing cell death via caspase activation [71] (Fig. 3). 
 
 
Figure 3: RIG-I-like helicase signaling  
Viral RNA is sensed by RIG-I through the 5’-triphosphate moiety or by MDA5 due to the double 
stranded nature of the RNA. Both receptors signal via the mitochondrial adaptor protein MAVS, 
which leads to type I IFN and pro-inflammatory cytokine production, as well as cell death 
induction.  
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1.3.2 RLH-based tumor immunotherapy 
The helicases MDA5 and RIG-I can be activated by synthetic RNA ligands such as 
polyinosinic:polycytidylic acid (poly(I:C)) and in vitro transcribed 5’-triphosphate RNA 
(ppp-RNA), respectively. Both, poly(I:C) and ppp-RNA can form complexes with 
polyethylenimine (PEI), which ensures intracellular delivery via transfection. Treatment 
of pancreatic cancer cells with poly(I:C) or ppp-RNA induces immunogenic cell death 
and secretion of pro-inflammatory cytokines [46]. In vivo, treatment with RLH ligands 
activates the immune system, induces a systemic type I IFN response and increases 
survival of mice with pancreatic cancer [47, 72].  
 
1.3.3 Role of type I IFN in cancer  
Type I IFN such as IFN- and IFN- play dichotomous roles in cancer. They are 
produced and sensed by tumor cells as well as non-tumor cells via the type I IFN receptor 
(IFNAR) [73]. On the one hand, type I IFN induce MHC class I expression on the surface 
of tumor cells and enhance their antigen presentation [74]. On the other hand, type I IFN 
has been described to facilitate metastasis and induce stem cell properties in tumor cells 
[75]. In addition, type I IFN increases the expression of immunosuppressive markers 
such as PD-L1 [76]. In immune cells, acute type I IFN has many beneficial functions by 
increasing antigen-presentation of DC and by activating natural killer (NK) cells as well 
as cytotoxic T cells [73]. However, during chronic type I IFN stimulation, suppressive 
mechanisms are induced [77]. There is increasing evidence that, in addition to PD-L1, 
the expression of PD-1 on MDSC is induced under inflammatory conditions [78, 79].  
 
1.4 Interferon regulatory factor 4 (IRF4) 
1.4.1 Family of IFN regulatory factors (IRF) 
IRF4 is one of nine members of the IFN regulatory factors (IRF) family. All IRF proteins 
share a conserved N-terminal DNA binding domain that recognizes IFN-stimulated 
response elements (ISRE) and thereby regulate transcription. The C-terminal region 
varies between the different members. Initially, IRF proteins have been described to 
regulate IFN signaling. In the past decade, more and more functions of IRF proteins in 
immune system processes have been discovered, making IRF proteins important 
regulators of immune cell differentiation and function. In addition, IRF protein functions 
have been linked to oncogenesis and metabolism. In general, IRF proteins are key 
regulators of the pattern recognition receptor (PRR) signaling and the induction of pro-
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inflammatory cytokines. In contrast to all other IRF proteins, IRF4 is a negative regulator 
of toll-like receptor (TLR)-induced cytokine induction [80].  
 
IRF5 mediates pro-inflammatory cytokine induction upon TLR activation by binding to 
myeloid differentiation primary response 88 (MyD88) and activates Irf4 transcription. 
IRF4 competes for the same MyD88 binding site as IRF5, but does not induce pro-
inflammatory cytokines und thereby limits the inflammatory response [81]. 
 
The binding affinity of IRF4 alone to DNA is low. The recruitment to the DNA binding site 
relies on its interaction with other transcription factors including PU.1 and PR domain 
zinc finger protein 1 (BLIMP1, encoded by the Prdm1 gene) which influence the binding 
affinity to IRSE or AP1 elements [82]. Thereby, the different complexes regulate the 
development and function of lymphoid as well as myeloid cells. 
 
1.4.2 Role of IRF4 in lymphoid cells 
IRF4 and IRF8 share redundant functions in the early development of B cells. IRF4 is 
crucial during later stages of B cell maturation. IRF4 regulates the isotype switching 
during the plasma cell differentiation by transcriptional induction of activation-induced 
cytidine deaminase (Aid) and Blimp1 [83, 84]. Therefore, IRF4-deficient mice have 
physiological numbers of mature B cells, however, the concentration of high affinity 
immunoglobulin G (IgG) antibodies is dramatically reduced [80]. 
 
T cells play a central role in adaptive immunity. CD4+ T helper cell subsets regulate B cell 
and macrophage function, whereas CD8+ T cells kill infected or transformed target cells. 
IRF4 plays a pivotal role in T cells. Under physiological, uninfected conditions, T cell 
frequency is not altered in IRF4-deficient mice and IRF4 is dispensable for early T cell 
development. However, IRF4 is induced upon T cell receptor (TCR) engagement and is 
an essential transcriptional regulator of the induction of cytolytic activity [85], metabolic 
reprograming [86] as well as the induction of activation-induced expansion of CD8+ 
T cells [87, 88]. IRF4-deficient mice are more susceptible to virus infections [88] and to 
infections by intracellular pathogens [85] due to the lack of functional CD8+ T cells as 
well as B cells.  
 
CD4+ T helper (Th) cells differentiate into different subsets such as Th1, Th2, Th9, 
Th17 cells depending on the cytokine milieu during antigen-specific stimulation [89]. IL-4 
differentiates naïve T cells (Th0) to Th2 cells by inducing IRF4 expression, which 
cooperates with NFAT transcription factors in inducing the GATA3-dependent Th2 
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differentiation program [90]. Therefore, IRF4-deficient CD4+ T cells fail to differentiate 
into functional Th2 cells [91]. Moreover, IRF4 is involved in the differentiation of Th9 by 
regulating the expression of IL-9 [92]. Furthermore, IRF4 is pivotal for the differentiation 
of naïve CD4+ T cell into Th17 cells [93]. Under Th17 polarizing conditions, IRF4 is 
phosphorylated and subsequently regulates the transcription of RAR-related orphan 
receptor (RORt), the Th17 fate-defining transcription factor [94]. IRF4-deficient mice are 
resistant to the Th17-mediated disease experimental autoimmune encephalomyelitis 
(EAE) [95]. In addition, IRF4 controls effector function of regulatory T cells (Treg) by 
regulating IL-10 expression [96] (Fig. 4). 
 
 
Figure 4: IRF4 function in immune cell subsets 
IRF4 is expressed by myeloid and lymphoid immune cells. IRF4 regulates M2 macrophage 
polarization, MDSC development, cDC2 development and moDC development. IRF4 is the key 
transcription factor for the class switch of plasma cells, for effective CD8+ T cell function, Th2, 
Th9 and Th17 development, as well as Treg function. 
 
1.4.3 Role of IRF4 in myeloid cells 
Myeloid cells consist of monocytes, macrophages, granulocytes and DC and derive from 
the hematopoietic stem cells and the common myeloid progenitor cells (CMP). IRF4 and 
IRF8 share structural and functional characteristics and are described to play a critical 
role in myelopoiesis. Initially, it has been described that both, IRF8 and to a lesser extent 
IRF4, are expressed in granulocyte-macrophage progenitors (GMP), common myeloid 
progenitor (CMP), macrophages, granulocytes and DC. IRF4-deficient mice have only a 
minor change in the frequency of myeloid cells, whereas the number of granulocytes is 
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dramatically increased, and the frequency of macrophages is reduced in IRF8-deficient 
mice [97]. Recent data challenge the expression of IRF4 in myeloid progenitor cells [98].  
 
There are four main groups of dendritic cells (DC): monocyte-derived DC (moDC), 
plasmacytoid DC (pDC), conventional type1 DC (cDC1) and conventional type2 DC 
(cDC2) [99]. cDC1 represent a migratory cross-presenting subtype which is essential for 
effective anti-tumoral T cell response. The role of cDC2 in cancer is still unclear. cDC2 
take up antigens in the tumor microenvironment and migrate to the draining lymph node, 
however, cDC2 are dispensable for the induction of T cell responses [100]. In the 
development of conventional DC, IRF4 and IRF8 play opposing roles. IRF4 is one of the 
linage-defining transcription factors in the differentiation of cDC2. However, it is 
dispensable for cDC1 differentiation. In contrast, IRF8 is pivotal for the differentiation of 
cDC1 [99]. IRF4-deficient mice have dramatically reduced numbers of cDC2 in lung and 
spleen whereas cDC1 are unaffected [101]. Recently, it has been shown, that 
differentiation of Ly6C+ monocytes to moDC, which are capable of cross-presenting 
antigens, requires IRF4 [102].  
 
Macrophages can be polarized into a classically activated pro-inflammatory M1 or an 
alternatively activated anti-inflammatory M2 state. IL-4 and IL-13 induce M2 macrophage 
polarization by activation of the epigenetic regulator jumonji domain containing protein 
D3 (JMJD3). JMJD3 removes inhibitory methyl marks on histone H3 Lys 27 (H3K27) of 
the Irf4 promoter region and thereby facilitates IRF4 expression. Subsequently, 
expression of suppressive proteins such as ARG1 is transcriptionally regulated by IRF4. 
JMJD3-deficient mice fail to mount a M2 immune response against helminths [103]. 
Tumor-associated macrophages are M2 polarized with immune suppressive and 
vascular remodeling potential. 
 
The role of IRF4 in granulocytes is still unclear. Ectopic expression or induction by IL-4 
or by the drug simvastatin blocked the differentiation of granulocytes in vitro [104]. The 
expression of IRF4 is gradually down-regulated in PMN-MDSC in a model of 4T1 breast 
cancer, accompanied by an induction of ARG1 and an increase in suppressive capacity 
[104] (Fig 4).   
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1.5 Objective     . 
PDAC is characterized by potent resistance mechanisms against conventional tumor 
therapies, such as chemotherapy, targeted therapy and radiation therapy. Despite 
intensive research, survival of patients suffering of PDAC has barely improved over the 
last decades. In several tumor entities immunotherapy has shown efficacy and is on the 
verge to become standard of care. However, in PDAC a potent immunosuppressive 
microenvironment is found with expansion of myeloid cells such as MDSC, opposing 
effective immune responses. A profound understanding of the regulation and function of 
MDSC in pancreatic cancer may help to develop novel immune-mediated treatment 
strategies for PDAC.  
 
This study aims at improving the understanding of the role of the myeloid cell 
compartment in pancreatic cancer in murine PDAC. The specific objectives are:  
1) To characterize the immune cell composition and specifically MDSC recruitment 
in a KPC-derived PDAC model 
2) To investigate functional properties of MDSC as targets of RLH-based 
immunotherapy of PDAC  
3) To characterize the role of IRF4 in MDSC differentiation and function in PDAC  
 
 
Figure 5: Working model 
Tumor-derived factors alter the development of myeloid cells by inducing immune suppressive 
cells such as MDSC. In this study the impact of MDA5-targeting immunotherapy on MDSC and 
the role of IRF4 in MDSC in development and function was analyzed. 
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2. Material and methods 
2.1 Material     . 
2.1.1 Technical equipment 
Name Company 
Bioanalyzer 2100 Agilent, USA 
Cell culture CO2 incubator (BD 6220) Heraeus, Germany 
Cell culture Laminar Flow Thermo Scientific, Germany 
Centrifuge (Multifuge 3L-R) Thermo Scientific, Germany 
Centrifuge (5424 and 5415R) Eppendorf, Germany 
ChemiDoc™ Imaging Systems Bio-Rad, Germany 
Multi plate reader (Mithras LB940) Berthold Technologies, Germany 
FACSCanto II BD Bioscience, Germany 
FACS Fortessa BD Bioscience, Germany 
Gel electrophoresis system peqlab, Germany 
gentleMACS Dissociator Miltenyi Biotec 
NextSeq 500 Sequencer Illmuina, USA 
LightCycler® 480 II Roche, Germany 
Microscope Axiovert25 and Axiovert200M Zeiss, Germany 
NanoDrop® 2000c Thermo Scientific, Germany 
pH meter WTW, Germany 
Thermocycler T3 Biometra, Germany 
 
2.1.2 Chemicals and reagents 
Name Company 
7-Aminoactinomycin D  Sigma-Aldrich, USA 
3,3-Diaminobenzidine (DAB) Dako, US 
Bovine serum albumin Roth, Germany 
Chloroform Roth, Germany 
DC Protein Assay (Bradford) Bio-Rad, Germany 
Dimethyl sulfoxide Roth, Germany 
Dulbecco’s PBS Lonza, Belgium 
Ethanol Sigma-Aldrich, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Germany 
Elisa Substrate Reagent A/B BD Pharmingen, USA 
Fixable viability Dye (FVD) life technologies, Germany 
Geneticin (G418) ThermoFisher, Germany 
Heparin-Natrium Braun Rathiopharm, Germany 
Isopropanol Applichem, Germany 
KAPA PROBE FAST Universal qPCR Master Mix peqlab, Germany 
Lipofectamine life technologies, Germany 
Lipofectamine RNAiMax life technologies, Germany 
Novagen Genejuice® transfection  Merck, Germany 
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Pharmlyse BD Bioscience, Germany 
Phenol-chlorofrom isoamyl alcohol Sigma-Aldrich, Germany 
Primer-probe mix, 10x conc. Roche, Germany 
Propidium iodide Sigma-Aldrich, Germany 
Sodium azide (NaN3) Sigma-Aldrich, Germany 
Sulfuric acid (H2SO4, 2N) Pharmacy, LMU Munich, 
Germany 
TMB Substrate Reagent Set BD Bioscience, Germany 
Trypan blue Sigma-Aldrich, Germany 
Trypsin-EDTA(10x) PAA, Austria 
Tween® 20 Roth, Germany 
 
2.1.3 Antibodies 
The following antibodies were used for flow cytometry: 
Specificity 
Fluoro-
chrome 
Species/isotype Clone 
Concen-
tration 
Company 
CD3 APC hamster/IgG1 145-2C11 1:100 BD Bioscience 
CD3 PB rat/IgG2b 17A2 1:200 BioLegend 
CD4 PB rat/IgG2a RM4-5 1:200 BioLegend 
CD4 FITC rat/IgG2a RM4-5 1:200 BioLegend 
CD4 PE-Cy7 rat/IgG2a RM4-5 1:200 BioLegend 
CD4 PerCP rat/IgG2a RM4-5 1:200 BioLegend 
CD8a 
APC-
Cy7 
rat/IgG2a 53-6.7 1:200 BioLegend 
CD8a PB rat/IgG2a 53-6.7 1:200 BioLegend 
CD8a PerCP rat/IgG2a 53-6.7 1:200 BioLegend 
CD8a BV786 rat/IgG2a 53-6.7 1:200 BioLegend 
CD11c APC hamster/IgG N418 1:200 BioLegend 
CD11c BV605 hamster/IgG N418 1:200 BioLegend 
CD19 PE-Cy7 rat/IgG2a 6D5 1:200 BioLegend 
CD45R/ 
B220 
PE-Cy7 rat/IgG2a RA3-6B2 1:200 BioLegend 
CD69 FITC hamster/IgG1 H1.2F3 1:100 BD Pharmingen 
CD69 APC hamster/IgG1 H1.2F3 1:100 Biolegend 
CD86 PE-Cy7 rat/IgG2a GL-1 1:100 BioLegend 
Ly6G BV786 rat/IgG2a, κ 1A8 1:200 BioLegend 
Ly6C FITC rat/IgG2c, κ HK1.4 1:200 BioLegend 
Ly6C PB rat/IgG2c, κ HK1.4 1:200 BioLegend 
CD11b PerCP rat/IgG2b, κ M1/70 1:200 BioLegend 
PD-1 PE rat/IgG2a, κ 29F1A12 1:200 BioLegend 
PD-1 APC rat/IgG2a, κ 29F1A12 1:200 BioLegend 
PD-L1 PE rat/IgG2a 10F.9G2 1:200 eBioscience 
CD45 AF700 rat/IgG2b, κ 30-F11 1:200 BioLegend 
NK1.1 PerCP mouse/IgG2a PK136 1:200 BioLegend 
NK1.1 BV605 mouse/IgG2a PK136 1:200 BioLegend 
MHC-I FITC mouse/IgG2a AF6-88.5 1:200 BioLegend 
MHC-II FITC mouse/IgG2a AF6-120.1 1:200 BD Pharmingen 
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MHC-II PB mouse/IgG2a AF6-120.1 1:200 Biolegend 
IRF4 AF647 rat/IgG1, κ IRF4.3E4 1:100 Biolegend 
Gr1 PE rat/IgG2b, κ RB6-8C5 1:200 Biolegend 
Isotype 
Ctrl. 
AF647 rat/IgG1, κ RTK2071 1:100 Biolegend 
Isotype 
Ctrl. 
PE rat/IgG2, κ RTK2758 1:200 Biolegend 
Isotype 
Ctrl. 
FITC 
Armenian 
Hamster IgG 
HTK888 1:200 Biolegend 
Isotype 
Ctrl. 
APC 
Armenian 
Hamster IgG 
HTK888 1:200 Biolegend 
Isotype 
Ctrl. 
PE-Cy7 rat/IgG2, κ RTK2758 1:200 Biolegend 
Table 1: Antibodies for flow cytometry 
 
2.1.4 Assay kits 
Name Company 
Mouse GM-CSF DuoSet ELISA R&D Systems, USA 
Mouse G-CSF DuoSet ELISA R&D Systems, USA 
Mouse IL-6 DuoSet ELISA R&D Systems, USA 
Mouse CXCL10/IP-10/CRG-2 DuoSet ELISA R&D Systems, USA 
FAM-FLICA® Caspase-8 Assay Kit ImmunoChemistry Techn, USA 
eBioscience™ Foxp3 / Transcription Factor   
Staining Buffer Set Thermo Fisher, Germany 
Tumor Dissociation Kit®  Miltenyi, Germany 
Myeloid-derived suppressor cell (MDSC)   
isolation Kit Miltenyi, Germany 
Pan T cell isolation Kit II, mouse Miltenyi, Germany 
QIAzol Kit QIAGEN, Germany 
RNeasy Kit, QIAGEN, Germany 
Agilent RNA 6000 Pico Kit Agilent, USA 
Agilent DNA 1000 Kit Agilent, USA 
SMARTer® Stranded Total RNA-Seq Kit v2  
 - Pico-input mammalian total RNA kit Takara, Japan 
NextSeq® 500/550 High Output Kit v2 (150 cycle) Illumina  
 
 
2.1.5 Cell lines 
Murine pancreatic cancer cell lines that were isolated from spontaneous genetically 
engineered mouse models (GEMM) were obtained from Prof. Saur (Innere Medizin II, 
Klinikum der Technischen Universität (TU) Munich) and Prof. Siveke (West German 
Cancer Center, University Hospital Essen). All cell lines were tested positive for 
cytokeratin 18 and negative for fibroblast activation protein (FAP). Genetic background 
of mice, of which the cell lines have been generated from, are listed in table 2. 
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Splenocytes from PD-1 knockout mice (B6.Cg-Pdcd1tm1.1Shr/J) were a kind gift from 
Dr. Festag and Prof. Protzer (Institute of Virology, TU Munich)  
 
Cell line name Detailed genotype 
8024 p48-Cre +/-, LSL-Kras +/- 
8025 p48-Cre +/-, LSL-Kras +/- 
R254 p48-Cre +/-, LSL-Kras +/-, LSL-Trp53R172H 
8028 p48-Cre +/-, LSL-Kras +/- 
8305 p48-Cre +/-, LSL-Kras +/- 
8661 p48-Cre +/-, LSL-Kras +/- 
9203 p48-Cre +/-, LSL-Kras +/- 
13871 Low-Cre +/-, LSL-Kras +/-, p53 lox/lox 
MG 846 Pdx1-Cre +/-, LSL- Kras +/-, p53 lox/+ 
T110299 Ptf1aCre +/-, LSL-KrasG12D, p53fl/R172H 
Table 2: Pancreatic tumor cell lines 
 
2.1.6 Cell culture, supplements and cytokines 
Name Company 
β-mercaptoethanol Sigma-Aldrich, Germany 
Dulbecco’s modified Eagls’s medium  
(DMEM), high glucose Sigma-Aldrich, Germany 
Dynabeads® Mouse T activator CD3/CD28 life technologies, Germany 
Fetal bovine serum (FBS) life technologies, Germany 
L-glutamine (200 mM) Sigma-Aldrich, Germany 
MEM-NEAA (non-essential amino acids) life technologies, Germany 
Penicillin/Streptomycin (100 x)  Lonza, Germany 
Opti-MEM life technologies, Germany 
OVA257-264 peptide (SIINFEKL) InvivoGen, USA 
OVA protein Sigma-Aldrich, Germany 
Roswell Parl Memorial Institute (RPMI) 1640 medium Sigma-Aldrich, Germany 
Sodium pyruvate Sigma-Aldrich, Germany 
Recombinant murine GM-CSF Peprotech, Germany 
Recombinant murine IL-4 Peprotech, Germany 
Recombinant murine IL-13 Peprotech, Germany 
2.1.7 Material animal experiments 
Name Company 
Sodium chloride, pyrogen-free (NaCl 0.9%) Baxter, UK 
Buprenovet (Buprenorphin) Bayer, Germany 
Midazolam-hameln (Benzodiazepin) hameln, Germany 
Dorbene vet (Medetomidin) zoetis, Germany 
Flumazenil Hikma (Benzodiazepin-Antagonist) Hikma, Germany 
Alzane (Atipamezol) Pfizer, USA 
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In vivo-JetPEITM Polyplus transfection, USA 
Isoflurane-CP® CP-Pharma, Germany 
Bepanthen (Augen und Nasensalbe) Bayer, Germany 
Aqua ad injectabilia  Braun AG, Melsungen, DE 
Poly(I:C)-HMW (high molecular weight), vaccigrade  Invivogen, USA 
Surgery and dissecting set, autoclaved  RSG, Germany 
Capillary tube, heparinized Hirschmann, Germany 
Insulin U-100 0.3 ml BD Microfine, Germany 
Scalpel (No. 22) Feather, Japan 
SurgiproTM II P-13 5-0 Covidien, Ireland 
 
Anesthesia: 
Drug 
Stock 
concentration 
amout for 
injection mix 
Vol for 
injection mix 
Dorbene 1 mg/ml 0.5 mg 500 µl 
Midazolam 5 mg/ml 5 mg 1 ml 
NaCl (0,9%)   1 ml 
Buprenorphin 0.324 mg/6 ml 0.0675 mg 1.25 ml 
➔ 150 µl/mouse 
 
Antidote: 
Drug 
Stock 
concentration 
amout for 
injection mix 
Vol for 
injection mix 
Flumazenil 0.1 mg/ml 0.5 mg 5 ml 
Alzane 5 mg/ml 2.5 mg 500 µl  
➔ 110 µl/mouse 
2.1.8 Buffer compositions 
DNA isolation buffer for genotyping: 
Lysis buffer: 25 mM NaOH, 0.2 mM EDTA in H2O 
Neutralization buffer: 40 mM Tris-HCl in H2O 
 
FACS buffer:  MACS buffer: 
2 mM EDTA 2 mM EDTA 
2 % FBS 5% BSA 
0.1 % NaN3 in PBS 
in PBS 
 
2.1.9 Primer and oligonucleotide sequences 
Name Sequence 5`->3` 
Ly6G_wt_ctrl_fwd GAGACTCTGGCTACTCATCC 
Ly6G_wt_ctrl_rev CCTTCAGCAAGAGCTGGGGAC 
Ly6G_Cre_1_fwd GGTTTTATCTGTGCAGCCC 
Ly6G_Cre_rev GAGGTCCAAGAGACTTTCTGG 
Ly6G_Cre_2_fwd ACGTCCAGACACAGCATAGG 
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Irf4-fl_geno1_fw TGGGCACCTCTACTGTCTGG 
Irf4-fl_geno2_rv CTCTGGGGACATCAGTCCT 
Irf4-fl_geno3_rv CGACCTGCAGCCAATAAGC 
FLP_tg_geno1_fw TGCCGGTCCTATTTACTCGT 
FLP_tg_geno1_rv TACTTCTTTAGCGCAAGGGGTAG 
FLP_wt_geno1_fw CTAGGCCACAGAATTGAAAGATCT 
FLP_wt_geno1_rv GTAGGTGGAAATTCTAGCATCATCC 
LysM_geno1_fw CCCAGAAATGCCAGATTACG 
LysM_geno_rv CTTGGGCTGCCAGAATTTCTC 
LysM_geno2_fw TTACAGTCGGCCAGGCTGAC 
IRF4-wt-for-A2 TGCCTTTGGGACGGATGCTC 
IRF4-wt-rev-B2 CTTCTAGCTGACCACTAAGAAC 
IRF4-frt-rev-D AATCAAGTGTGGGCAAGACTG 
pOVA_fwd TCCTCAACCAAATCACC 
pOVA_rev AGACAATGGCATTAACC 
Table 3: Primers for PCR 
 
Name Sequence 5`->3` Probe No 
Cytokeratin8_fw AGTTCGCCTCCTTCATTGAC 67 
Cytokeratin8_rv GCTGCAACAGGCTCCACT 67 
Cytokeratin18_fw AGATGACACCAACATCACAAGG 78 
Cytokeratin18_rv TCCAGACCTTGGACTTCCTC 78 
Cytokeratin19_fw AGTCCCAGCTCAGCATGAA 97 
Cytokeratin19_rv TAACGGGCCTCCGTCTCT 97 
FAP_fw CGTGTATCGAAAACTGGGTGT 100 
FAP_rv AAACCCATTTCTATGAATTTTCTGAC 100 
beta-actin_fw CTA AGG CCA ACC GGG AAA AG 64 
beta-actin_rv ACC AGA GGC ATA CAG GGA CA 64 
Table 4: Primers for quantitative PCR 
 
Name Sequence 5`->3`1 
sgRNA1_fwd GTCGTCTCCCACCGAGCCCCTCGCCCAAACCAGAGTTTCGAGACGTG 
sgRNA1_rev CACGTCTCGAAACTCTGGTTTGGGCGAGGGGCTCGGTGGGAGACGAC 
sgRNA2_fwd GTCGTCTCCCACCGCGGAGGATCTTATGCTGAACGTTTCGAGACGTG 
sgRNA2_rev CACGTCTCGAAACGTTCAGCATAAGATCCTCCGCGGTGGGAGACGAC 
Table 5: Oligonucleotids for molecular cloning 
 
                                               
1 sgRNA targeting sequence are indicated with bold and underlined letters 
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2.1.10 Consumables 
Name Company 
Cryo`sTM Greiner Frickenhausen, Germany 
1.5 ml reaction tubes Eppendorf, Hamburg, DE 
Polystyrene round-bottom tubes Dickinson, San Jose, USA 
PCR-Tubes Biozym Hess, Germany 
MACS® SmartStrainers (30 µm, 70 µm, 100 µm) Miltenyi Biotec, Germany 
Cell scraper Sarstedt, Germany 
1 ml disposable syringe Norm-Ject Henke Sass Wolf, Germany 
Syringe (5 ml, 20 ml) Becton Dickinson, USA 
Injection needle (27 G 3/4 0.4x19 mm) Becton Dickinson, USA 
Cell culture flasks (175 cm3, 75 cm3) Greiner, Germany 
6-well cell culture plate Becton Dickinson, USA 
96-well cell culture plate round bottom Greiner, Germany 
 
2.2 Methods   . 
2.2.1 Cell biological methods 
2.2.1.1 Cell culture 
Tumor cells were cultured in DMEM supplemented with 10 % fetal bovine serum (FBS), 
2 mM L-glutamine, 100 U/l penicillin and 100 µg/ml streptomycin. Primary cells were 
cultured in RPMI-1640 medium supplemented with 10 % FBS, 2 mM L-glutamine, 
100 U/l penicillin, 0.1 mg/ml streptomycin, 100 mM non-essential amino acids, 1 mM 
sodium pyruvate and 50 mM 2-mercaptoethanol. All cells were cultured in a humidified 
incubator at 37 °C with 5 % CO2. All cells were frequently tested for mycoplasma 
contamination.  
 
2.2.1.2 Generation of tumor-conditioned medium 
2 x 105 tumor cells per 2 ml medium were seeded in a 6-well plate. After 48 h, 
supernatant was harvested, and cells were removed by centrifugation (400 x g, 5 min). 
Tumor conditioned medium was stored at -20 °C until usage.  
 
2.2.1.3 Bone marrow-derived cell culture 
Bone marrow cells were isolated by flushing femur and tibia. 2 x 106 cells per 10 ml were 
seeded in a 10 cm cell culture round plate in primary cell medium supplemented with 
20 ng/ml GM-CSF. 25 % tumor-conditioned medium was added as indicated. Three days 
later, 10 ml primary cell medium with the above-mentioned supplements was added. Five 
days after cell isolation, 66 % of the medium with the respective supplements was 
exchanged.  
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2.2.1.4 Flow cytometry 
Single cell suspension was washed in FACS buffer. Subsequently, cells were stained 
with primary fluorochrome-conjugated antibodies, with dilutions as indicated in Table 1. 
After 30 min incubation on ice, cells were washed with FACS buffer and resuspended in 
100 to 300 µl FACS buffer. Intracellular antigens were stained using the transcription 
factor staining buffer set, according to manufacturer’s protocol. In brief, after extracellular 
antigen staining, cells were fixed and permeabilized for 30 min at 4 °C. Subsequently, 
cells were washed with permeabilization buffer, incubated for 30 min at 4 °C with 
antibodies against respective intracellular antigens, and washed with permeabilization 
buffer. Samples were resuspended in FACS buffer and analyzed on a Canto II or 
LSRFortessa flow cytometer.  
 
Measurement of caspase activity in MDSC was done using the FAM FLICATM Caspase 8 
kit, according to manufacturer’s protocol. Briefly, splenic MDSC were incubated for 1 
hour with the FLICA reagent at 37 °C. Cells were washed and surface antigens were 
stained. Finally, cells were washed again and resuspended in FACS buffer. Samples 
were analyzed on a Canto II flow cytometer.  
 
2.2.1.5 T cell isolation and CFSE labeling  
Splenic T cells were isolated by negative selection using the Pan T Cell Isolation Kit II. 
Purity was controlled by flow cytometry and reached > 95 %. T cells were labeled with 
2.5 µM CFSE in 10 ml PBS by incubating 4 min at RT. Subsequently, staining reaction 
was stopped by adding 20 ml FBS. T cells were isolated by centrifugation (400 x g, 
5 min) and resuspended in primary cell medium. 
 
2.2.1.6 T cell suppression assay 
CFSE-labeled wild-type T cells were transferred into a 96-well plate, at 5 x 104 cells per 
well. Suppressive effector cells were isolated as described (see 2.2.2.6 MDSC isolation 
and 2.2.1.7 FACSorting). A serial dilution of suppressive effector cells (5 x 104, 2.5 x 104, 
1.25 x 104, 0.625 x 104 or 0.3125 x 104) was added to CFSE-labeled T cells. Anti-
CD3/anti-CD28 beads were washed once in PBS and subsequently resuspended in 
primary cell medium. 1 µl beads was added to each well. CFSE-labeled T cell controls, 
either with or without anti-CD3/anti-CD28 beads, were included. Cells were incubated 
for 72 h and CFSE-dilution of proliferating CD4+ and CD8+ T cells was analyzed by flow 
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cytometry. CFSE-labeled T cells without stimulation were used to set the CFSElow T cell 
proliferation threshold. 
 
2.2.1.7 FACSorting 
Bone marrow cells were isolated by FACSorting for T cell suppression assays as well as 
splenic and tumor-derived MDSC for RNA isolation. FACSorting was performed by 
PD Hristov on a BD Aria III flow cytometer. Cell preparation was performed as described 
(see 2.2.2.6 MDSC isolation) and cells were stained as described (see 2.2.1.4 Flow 
cytometry). PMN-MDSC and M-MDSC were sorted using following marker set: FVD-, 
CD45+, CD11b+, Ly6G+, Ly6Cint (PMN-MDSC) and FVD-, CD45+, CD11b+, Ly6G-, 
Ly6Chigh (M-MDSC), respectively. Post sort quality was controlled by flow cytometry. 
 
2.2.1.8 Generation of OVA overexpressing T110299 
An ovalbumin (OVA) overexpressing T110299 tumor cell line (T110299-OVA) was 
generated by PD Düwell. Briefly, cells were transiently transfected with the pAc-Neo-
OVA plasmid [105] using the Novagen Genejuice® transfection reagent, according to the 
manufacturer’s instructions. Cells were maintained in tumor cell medium, supplemented 
with G418 (geneticin) as selection reagent. OVA expression was confirmed by PCR. 
 
2.2.1.9 Antigen presentation assay 
Splenic OVA-specific transgenic OT-I T cells (C57BL/6-Tg(TcraTcrb)1100Mjb/J) were isolated 
and CFSE-labeled as described before (see 2.2.1.5 T cell isolation and CFSE labeling). 
5 x 104 CFSE-labeled OT-I T cells per well were transferred into a 96-well plate. MDSC 
as potential antigen presenting effector cells were isolated as described before (see 
2.2.2.6 MDSC isolation). A serial dilution of T110299-OVA tumor-derived MDSC (5 x 104, 
2.5 x 104, 1.25 x 104, 0.625 x 104 and 0.3125 x 104) were added to CFSE-labeled OT-I T 
cells, without stimulating beads. Splenic MDSC were either loaded with SIINFEKL 
peptide at indicated concentrations or were incubated over night at 37°C with 1 µg/ml 
OVA protein. Subsequently, OVA antigen treated MDSC were washed, resuspended in 
primary cell medium, diluted and seeded as described above. Cells were incubated for 
72 h at 37° C and CFSE-dilution of proliferated CD8+ OT-I T cells was analyzed by flow 
cytometry. CFSE-labeled OT-I T cells without stimulation were used to set the threshold 
for proliferated T cells (CFSElow). 
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2.2.1.10 CRISPR knockout generation 
Pdcd1 (PD-1/CD279) knockout B3Z T cell lines were generated using a lentiviral 
CRISPR/Cas9 approach as described [106, 107]. Pdcd1-targeting sgRNA sequences 
were retrieved from the GeCKOv2 mouse library (http://genome-
engineering.org/gecko/). A BsmBI restriction overhang was added as described [107]. 
The DNA sequence was ordered by eurofins genomics (see Table 5) and cloned into a 
pLentiCRISPRv2_ccdB_Cas9-P2A-Puro vector (kind gift from Prof. Schmidt-Supprian, 
III. Medizinische Klinik, TU Munich). HEK-293T cells were transfected with the 
CRISPR/Cas9 plasmid as well as with plasmids encoding the viral envelop proteins 
(pcMV_dR8-74 and pVSVG) using Lipofectamine® 2000. After 2 days, the lentivirus-
containing supernatant was transferred to B3Z cells. After additional 48 h, cells were 
treated with puromycin for positive selection. PD-1-negative B3Z cells were single-cell 
sorted into a 96-well plate using a BD FACSAriaTM III cell sorter. 
 
2.2.2 Animal experiments 
All animal experiments were approved by the local authority (Regierung von Oberbayern, 
Munich, Germany; animal protocol number 55.2-1-54-2532-175-12). All experiments 
were done in the animal facility Tierhaltung Ziemssenstr. 1 (THZ) under specific 
pathogen-free (SPF) conditions. Sentinel mice were sent for health status monitoring to 
MFD diagnostics (Wendelsheim, Germany) quarterly.  
 
2.2.2.1 Mouse strains 
C57BL/6 wild-type mice were purchased from Janvier, France. Irf4flox mice (B6.129S1-
Irf4tm1Rdf/J) were a kind gift from Prof. Bopp (Institute of Immunology, Universitätsmedizin 
Mainz), Ly6GCre mice (C57BL/6-Ly6gtm2621(Cre-tdTomato)Arte) were a kind gift from Prof. 
Gunzer (Institute for Experimental Immunology and Imaging, University of Duisburg-
Essen), LysMCre mice (B6.129P2-Lyz2tm1(cre)Ifo/J) were a kind gift from PD Lech, (Institute 
of Clinical Biochemistry, Klinikum der Universität München). Ifnar-/- (B6.129S2-
Ifnar1tm1Agt) were a kind gift from Prof. Rothenfußer (Division of Clinical Pharmacology, 
Klinikum der Universität München) and OT-I mice (C57BL/6-Tg(TcraTcrb)1100Mjb/J) were a 
kind gift from PD Kobold (Division of Clinical Pharmacology, Klinikum der Universität 
München). FLP1 recombinase expressing FLPe mice (B6;SJL-Tg(ACTFLPe)9205Dym/J) were 
purchased from Jackson Laboratory (Sulzfeld, Germany).  
LysMCre were cross-bred with IRF4flox mice to obtain LysMCreIrf4flox and Ly6GCre were 
cross-bred with Irf4flox mice to obtain Ly6GCreIrf4flox. Both mouse strains were kept on 
Material and methods 24 
 
homozygous Irf4fl/fl background. Exon 4 of Irf4 in B6.129S1-Irf4tm1Rdf/J mice harbors two 
FRT sites, of which one is located upstream and one downstream of exon 4. To generate 
global IRF4-deficient mice, FLPe mice were cross-bred with B6.129S1-Irf4tm1Rdf/J mice 
and Irf4-/- mice were obtained. IRF4 sufficient mice originating from those breedings were 
used as littermate controls. Genotypes of all mice were routinely analyzed by PCR as 
described below (see 2.2.3.3 Genotyping PCR). 
 
2.2.2.3 Orthotopic tumor induction 
T110299 tumor cells were passaged at a 1:2 ratio the day prior surgery to ensure optimal 
growth behavior at the day of injection. The next day, tumor cells were washed three 
times with PBS to remove residing FBS completely. The surgery was performed under 
general anesthesia as well as analgesia applied intraperitoneally (i.p.) and eyes were 
protected from exsiccation using eye cream. The fur was disinfected and the skin as well 
as the peritoneal cavity was opened with an approximately 1 cm cut. Pancreatic tissue 
was carefully dislocated and 2 x 105 tumor cells in 25 µl PBS were injected into the tail 
of the pancreas. Organs were carefully relocated, and cuts were sewed. To antagonize 
general anesthesia, the antidote (see 2.1.7 Material animal experiments) was 
administered and the mice were kept under warming light. Mice were administered 
analgesia during the following 24 h and distressed mice were sacrificed. 
 
2.2.2.4 Treatment 
For in vivo treatment, high molecular weight poly(I:C) was complexed with invivo-jetPEI 
at a N/P ratio2 of 6, in 5 % glucose solution (Poly(I:C)c). Mice were treated i.v. with 50 µg 
poly(I:C)c or 5 % glucose solution (control) at day 18 and 20 after tumor induction. Mice 
were sacrificed at day 21.  
 
2.2.2.5 Survival  .  
For survival, health status of mice (body weight, general condition, spontaneous behavior 
and clinical status) was evaluated daily following the EU-severity assessment and 
according to the animal protocol´s score sheet. Mice were sacrificed as soon as they 
reached a severity score of three or higher.  
 
                                               
2 N/P ratio is the ratio of positively charged amino groups of PEI to negatively charged 
phosphate groups of the RNA molecule  
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2.2.2.6 MDSC isolation 
To isolate MDSC from the spleen, splenocytes were flushed out with a syringe and red 
blood cells were lyzed using BD PharmLyse. To isolate tumor-derived MDSC, tumors 
were cut into 1 to 2 mm² pieces and mechanically dissociated with the gentleMACS 
device (program imptumor2_2), in the presence of digestion enzymes by using the 
Tumor Dissociation Kit®.  
 
For functional assays, MDSC were isolated using MDSC MACS isolation. In brief, PMN-
MDSC were isolated with anti-Ly6G microbeads. Subsequently, M-MDSC were isolated 
from the negative fraction using anti-Gr1 microbeads. Purity was analyzed by flow 
cytometry. The purity of PMN-MDSC was > 90% and the purity of M-MDSC was > 70%. 
For RNA isolation, MDSC were enriched using CD11b+ MACS positive selection kit, 
followed by FACSorting (see 2.2.1.7 FACSorting).  
 
2.2.3 Molecular biology methods 
2.2.3.1 Enzyme-linked immunosorbent assay (ELISA) 
The concentration of G-CSF, GM-CSF, IL-6 and CXCL10 in serum or tumor-conditioned 
cell culture medium was measured by ELISA, according to manufacturer’s protocol. 
Briefly, 96-well plates were coated over night with capture antibody diluted in PBS and 
unspecific binding was blocked with 1 % BSA. Samples were added and incubated for 
2 h. After a washing step, biotinylated detection antibodies and streptavidin-coupled 
horse radish peroxidase (HRP) were added. HRP-mediated conversion of the 
tetramethylbenzidine (TMB) substrate was measured as absorbance at 450 nm with 
wavelength correction 570 nm by a multi-plate reader.  
 
2.2.3.2 DNA isolation for mouse genotyping 
DNA from ear or tail biopsies was extracted and analyzed as described before [108]. 
Briefly, biopsies were incubated in 75 µl alkaline lysis buffer for 30 min at 95°C and 
reaction was stopped by adding 75 µl neutralization buffer. Supernatant containing 
genomic DNA was subsequently used for genotyping. 
 
2.2.3.3 Genotyping PCR 
For genotyping of mice, isolated DNA was analyzed using locus specific primer pairs 
listed in Table 3, by using genotype-specific cycling programs, as summarized in 
Table 6.  
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IRF4flox 
94 °C, 
5 min 
94 °C, 
30 sec 
60 °C, 
30 sec 
72 °C, 
30 sec 
35 
72 °C, 
5 min 
IRF4-/- 
95 °C, 
5 min 
95 °C, 
15 sec 
62 °C, 
30 sec 
72 °C, 
60 sec 
30 
72 °C, 
5 min 
LysMCre 
94 °C, 
5 min 
94 °C, 
20 sec 
60 °C, 
15 sec 
72 °C, 
15 sec 
25 
72 °C, 
2 min 
Ly6GCre 
94 °C, 
5 min 
94 °C, 
30 sec 
60 °C, 
30 sec 
72 °C, 
60 sec 
35 
72 °C, 
10 min 
Ly6GWT 
94 °C, 
5 min 
94 °C, 
30 sec 
60 °C, 
30 sec 
72 °C, 
60 sec 
35 
72 °C, 
10 min 
FLP1 
94 °C, 
5 min 
94 °C, 
20 sec 
60 °C, 
15 sec 
72 °C, 
15 sec 
25 
72 °C, 
2 min 
OT-I 
94 °C, 
5 min 
94 °C, 
30 sec 
60 °C, 
30 sec 
72 °C, 
60 sec 
35 
72 °C, 
10 min 
Table 6: PCR cycling conditions for genotyping PCR 
 
2.2.3.4 RNA isolation 
For RNA sequencing, MDSC were isolated in a combined CD11b+ MACSorting and 
FACSorting approach. MDSC RNA was isolated using the QIAzol kit. In brief, cells were 
lyzed in trizol reagent. RNA was isolated by adding chloroform and was extracted using 
RNeasy RNA binding columns (RNeasy Kit, Qiagen). RNA concentration and rRNA 
integrity was measured using the Pico 6000 assay on a bioanalyzer 2100.  
 
2.2.3.5 RNA-Seq sample preparation and next generation sequencing 
The SMARTer® Stranded Total RNA-Seq Kit v2 - Pico-input mammalian total RNA kit 
was used to prepare the cDNA library for next generation sequencing. The library was 
prepared according to manufacturer’s protocol. In brief, after confirming high integrity of 
the RNA using the Agilent RNA 6000 Pico Kit on a Bioanalyzer 2100 (RIN > 7), RNA was 
fragmented for the maximum time frame (4 min at 94°C). Next, first-strand cDNA 
synthesis was performed using supplied random primers. Subsequently, Illumina 
adapters and indexes were added in a PCR step. The cDNA library was isolated for next 
generation sequencing using AMPure beads, and ribosomal sequences were depleted 
using ZapRv2 and R-Probes v2. Finally, the RNA-Seq library was amplified in 13 PCR 
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cycles and isolated using AMPure beads. cDNA fragment length and concentration were 
analyzed on the bioanalyzer 2100 using the Agilent DNA 1000 Kit. The library was loaded 
on an Illumina NextSeq® 500/550 High Output Kit v2 and analyzed on an Illmuina 
NextSeq sequenzer. Library loading and sequencing were performed by Dr. Rohlf (Care-
for-Rare Laboratories at the Dr. von Haunerschen Kinderspital, LMU, Munich).  
 
2.2.3.5 Complementary DNA (cDNA) synthesis  
cDNA was synthesized from RNA by RevertAIDTM first strand cDNA synthesis kit 
according to manufacturer’s protocol. In brief, master mix summarized in Table 7 was 
incubated for 1 h at 42°C, followed by a 5 min inactivation step at 70° C.  
 Stock concentration 1x reaction 
RNA  1000 ng 
Oligo(dT)18 10 µM 1 µl 
RibolockTM 20 U/µl 1 µl 
dNTP 10 mM 2 µl 
RevertAidTM 200 U/µl 1 µl 
5x Reaction buffer  4 µl 
H2O  up to 12 µl 
Table 7: Mastermix for cDNA synthesis 
 
2.2.3.6 Quantitative PCR (qPCR) 
Messenger RNA (mRNA) expression levels were analyzed by quantitative PCR (qPCR) 
using the Roche Universal probe library according to manufacturer’s protocol. In brief, 
the master mix summarized in Table 8 was mixed and subsequently analyzed on the 
Roche LightCycler 480 II using the program summarized in Table 9. 
 Stock concentration 1x reaction 
cDNA  3 µl 
Forward primer 10 µM 0.2 µl 
Reverse primer 10 µM 0.2 µl 
Probe  0.1 µl 
Kapa probe fast 
universal qPCR 
master mix (2x) 
 5 µl 
H2O  up to 10 µl 
Table 8: Mastermix for qPCR 
 Temperature  Time  Quantification  
Pre-incubation 95 °C 10 min None  
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Denaturation 95 °C 15 sec None 40 
Cycles Elongation 60 °C 60 sec Yes 
Cooling  40 °C oo None  
Table 9: Cycling program of LightCycler 
 
2.3 Computational analysis 
2.3.1 Statistical analysis 
Data are displayed as mean and standard deviation (SD) or standard error of the mean 
(SEM) as indicated in the figure legend. Generally, data with individual mice are shown 
as mean and SEM. To detect statistically significant differences between two groups, 
Mann Whitney U test was used. To compare more than two groups, we applied Kruskal-
Wallis test followed by posthoc tests between selected samples. To compare the 
influence of two independent variables e.g. treatment and genotype two-way analysis of 
variance (ANOVA) was conducted, followed by posthoc tests between selected samples. 
Spearman correlation analyses were performed to explore associations between 
potential influencing factors. To analyze differences in the survival, Mantel-Cox test was 
conducted. 
 
2.3.2 Bioinformatics analysis  
Whole transcriptomic sequencing results were kindly analyzed by Michael Kluge and 
Prof. Friedel (Institute for Informatics, Ludwig-Maximilians-Universität Munich) using the 
following procedure: Quality of sequencing reads was assessed using fastQC [109]. 
Reads were mapped against the mouse genome (mm10) and mouse rRNA sequences 
using ContextMap version 2.7.9 [110] (using BWA [111] as short read aligner and default 
parameters). Number of read fragments per gene were determined strand-specific from 
the mapped RNA-Seq reads using featureCounts [112] and Gencode (v16) annotations. 
Differential gene expression analysis was performed using DEseq2 [113]. P-values were 
adjusted for multiple testing using the method by Benjamini and Hochberg [114] and 
genes with an adjusted p-value <0.001 were considered significantly differentially 
expressed. The RNA-Seq analysis workflow was implemented and run using the 
workflow management system Watchdog [115]. Results were visualized using the online 
tool ClustVis [116]. Functional annotation was performed using DAVID Bioinformatics 
Resources 6.8 [117].  
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2.4 Software       . 
Name Company 
Adobe Illustrator CS6 Adobe Systems, USA 
EndNote X8 Thomson Reuters, USA 
FACSDiva BD Bioscience, Germany 
FlowJo V10 Tree Star, USA 
Graphpad Prism 7.0 Graphpad Software, USA 
LightCycler 480 SW 1.5 Roche, Germany 
ClustVis 1.0 https://biit.cs.ut.ee/clustvis/ 
DAVID 6.8 https://david.ncifcrf.gov/ 
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3. Results 
3.1 Induction of suppressive myeloid cells in a KPC-derived 
orthotopic model 
3.1.1 PDAC induce systemic myeloid cell expansion  
The tumor growth and immune cell composition of an orthotopic PDAC model using the 
KPC-derived pancreatic tumor cell line T110299 was characterized in vivo. T110299 
tumors were induced in the pancreas of C57BL/6 wild-type mice and organ weights as 
well as immune cell infiltrates were monitored (Fig. 6A). One week after tumor induction 
small tumors were detectable macroscopically. After three weeks, mice developed 
tumors with an average weight of 990 mg (Fig. 6B). Concordant to tumor growth, spleen 
weight increased without any sign of tumor cell metastasis into the spleen (Fig. 6B). 
Tumor and spleen weight correlated significantly (r = 0.78 p = 0.0001) (Fig. 6C).  
 
In the tumor tissue, PMN-MDSC (CD11b+Ly6G+Ly6Clow, Fig. 6A) frequency increased 
during tumor progression (p = 0.001) (Fig. 6D). M-MDSC (CD11b+Ly6G-Ly6Chigh, 
Fig. 6A) infiltrated the tumor initially; however the frequency dropped the following two 
weeks (p = 0.0005) (Fig. 6D). Gating strategy is depicted in Figure S1 and S2. CD4+ and 
CD8+ T cell frequency was significantly elevated at day 14 (CD4+ p = 0.02, CD8+ 
p < 0.0001) (Fig. 6D). The relative frequency of intratumoral immune cells 7, 14 and 21 
days after tumor induction is summarized in Fig. 1J.  
 
With increased tumor weight during tumor progress, the frequencies of both PMN-MDSC 
and M-MDSC were elevated in the spleen three weeks after tumor induction (p = 0.006, 
p = 0.003, respectively) (Fig. 6E). In contrast, CD8+ and CD4+ T cell frequency in the 
spleen decreased during tumor progression (p = 0.008, p = 0.003, respectively) 
(Fig. 6E). The frequency of both MDSC subpopulations in the blood increased during 
tumor growth (PMN-MDSC p = 0.009, M-MDSC p = 0.01), whereas the CD4+ and CD8+ 
T cell frequency remained constant (Fig. 6F). 
Results 31 
 
Figure 6: (continued) 
Results 32 
 
 
Figure 6: KPC-derived PDAC induce systemic expansion of the myeloid 
compartment. 
A) Experimental design: T110299 tumors were induced orthotopically in C57BL/6 mice. Organ 
weight (B) and immune cell frequency were measured by flow cytometry 0, 7, 14 and 21 days 
after tumor induction (D-F, I, J), and serum cytokine levels by ELISA 14 and 21 days after tumor 
induction (G). Tumor weight was correlated to spleen weight (C) and frequency of PMN-MDSC in 
the tumor (D). H) G-CSF serum levels were correlated to tumor weight and PMN-MDSC frequency 
in blood and spleen 14 and 21 days after tumor induction. I) Spearman correlation results of 
immune cell frequency (CD4+ T cells, CD8+ T cells, NK cells, NKT cells, PMN-MDSC, M-MDSC, 
Macrophages and B cells) in organ (tumor - blue, spleen - red, blood - black) with tumor weight. 
Statistical analysis was performed using Kruskal Wallis test, followed by Dunn’s multiple 
comparisons test between selected days (B, D-F) and spearman correlation (C, H) and unpaired 
student’s t-test (G). P values of Kruskal Wallis test and significant results of Dunn’s test are shown 
in each graph. n=4-5, error bars represent mean +/- SEM. Asterisks indicate * p < 0.05, ** p < 
0.01. N/A = not applicable.  
 
Myeloid cell stimulating cytokines such as GM-CSF and G-CSF have been described to 
mediate MDSC expansion [118, 119]. Interestingly, GM-CSF levels were not detectable 
in the serum of T110299 tumor bearing mice two and three weeks after tumor induction 
(Fig. 6G). In contrast, G-CSF levels were elevated in the serum of PDAC bearing mice 
(p = 0.075) (Fig. 6G). G-CSF concentration in the serum correlated significantly with 
tumor weight (p = 0.01, r = 0.71). Moreover, PMN-MDSC frequencies in both spleen and 
blood correlated significantly with G-CSF concentration in the serum (p = 0.001, r = 0.81) 
(Fig. 6H). To analyze the impact of the tumor weight on the immune cell composition, 
Results 33 
 
PMN-MDSC, M-MDSC, macrophage, DC, T cell and B cell frequency in blood, spleen 
and tumor was correlated to tumor weight. As shown in Fig. 1I, PMN-MDSC frequency 
in all three compartments and M-MDSC frequency in the spleen correlated positively with 
the tumor weight (p < 0.01). CD4+ T cell frequency in the spleen and NK cell frequency 
in the tumor correlated inversely with tumor weight (p < 0.01) (Fig. 6I).  
 
3.1.2 KPC-derived PDAC induce suppressive capacity in MDSC 
The PD-1/PD-L1 axis contributes to the immunosuppressive tumor microenvironment in 
many cancer entities [120]. PD-L1 expression was significantly elevated in the tumor 
microenvironment of both PMN-MDSC and M-MDSC compared to their splenic 
counterpart (p = 0.0001 and p = 0.0001, respectively; Fig. 7A). Similarly, PD-1 
expression of CD4+ and CD8+ T cells was low in the spleen and was significantly 
increased in the tumor (p = 0.0003 and p = 0.0002, respectively; Fig. 7B).  
 
The hallmark of MDSC in the context of tumors is their suppressive capacity. Both MDSC 
subtypes were isolated by MACS and co-cultured with anti-CD3/anti-CD28 stimulated 
T cells. T cell suppressive capacity of MDSC was measured by tracing T cell 
proliferation. Polymorphonuclear cells from the spleen of tumor-free hosts 
(granulocytes3) did not suppress CD8+ T cell proliferation (Fig. 7C). PMN-MDSC from 
tumor-bearing hosts showed dose-dependently CD8+ T cell suppressive capacity. 
Tumor-derived PMN-MDSC were the most potent T cell suppressors (Fig. 7C).  
 
Similar effects were revealed for M-MDSC: Monocytes3  from the spleen of tumor-free 
mice were not T cell suppressive whereas their counterparts from tumor-bearing hosts 
suppressed CD8+ T cell proliferation. Again, M-MDSC isolated from the tumor tissue 
showed a tendency towards higher suppressive capacity. Furthermore, both MDSC 
subtypes suppressed CD4+ T cell proliferation comparable to the inhibition of CD8+ T 
cells (Fig. 7D). 
 
Taken together, these data suggest that PDAC development modulates the immune 
system by systemic expansion of MDSC and induction of suppressive function in these 
cells.  
                                               
3 Granulocytes and PMN-MDSC as well as monocytes and M-MDSC are not distinguishable by flow 
cytometry. By definition PMN-MDSC and M-MDSC exist only under pathological conditions such as cancer 
and infection [18]. 
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Figure 7: KPC-derived PDAC induce T cell suppressive function in MDSC. 
PD-L1 expression of MDSC (A) and proportion of PD-1+ T cells (B) was analyzed by flow 
cytometry 0, 7, 14 and 21 days after orthotopic T110299 tumor induction. C-D) Three weeks after 
tumor induction, MDSC were isolated from tumor and spleen. Subsequently, MDSC were co-
cultured with CFSE-labeled T cells. The MDSC to T cell ratio was 0.25:1, 0.5:1 and.1:1. 
Proportion of proliferated CFSElow CD8+ (C) and CD4+ (D) T cells was analyzed by flow cytometry. 
Statistical analysis was performed using Kruskal Wallis test, followed by Dunn’s multiple 
comparisons test between selected days (A, B) n = 4-5. Figures C & D are representative graphs 
of three replicates with n = 4 mice per group, error bars represent mean +/- SEM. Asterisks 
indicate * p < 0.05, ** p < 0.01. 
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3.2 Characterization of PD-1 expression by MDSC 
3.2.1 Viable MDSC lack PD-1 expression  
There is increasing evidence, that not only PD-L1 but also its receptor PD-1 is expressed 
on myeloid cells including MDSC, and that intrinsic PD-1 signaling modifies cellular 
function [78, 121]. Thus, PD-1 expression was analyzed in MDSC in PDAC bearing mice. 
Anti-PD-1 staining was detectable in a subset of Gr1+ MDSC by flow cytometry. However, 
PD-1+ cells were smaller in size (FSC-Alow) and stained positive for the dead cell marker 
fixable viability dye (FVD) (Fig. 8A). This finding was confirmed with two additional dead 
cell markers, 7-AAD and cleavage of a caspase 8 substrate, which use different 
principles to define dead cells (Fig. 8B, C). To rule out unspecific binding of the antibody, 
an isotype staining control was used. Neither viable nor dead cell marker positive cells 
stained with the isotype control (Fig. 8B, right panel). 
 
3.2.2. Anti-PD-1 antibody binds to an unknown antigen in PD-1-deficient cells 
To analyze whether the anti-PD-1 antibody clone binds to another antigen than PD-1, 
wild-type and PD-1-deficient splenocytes were cultured for 48 h in the presence or 
absence of anti-CD3/anti-CD28 T cell stimulating beads. As expected, stimulation 
induced PD-1 expression on wild-type CD4+ T cells. No PD-1 staining was detectable on 
viable PD-1-deficient cells. However, in PD-1-deficient T cells, dead cell marker-positive 
cells stained positive for PD-1, indicating that the antibody binds to an antigen distinct 
from PD-1 in these cells (Fig. 8D).  
 
To confirm this finding, Pdcd1 was knocked-out in a T cell myeloma hybrid cell line (B3Z), 
which expresses PD-1 at high levels. Single cell clones were generated, and anti-PD-1 
staining was analyzed. To increase the proportion of dead cells, B3Z cells were treated 
with the apoptosis inducing agent staurosporine. Scrambled guideRNA-treated 
(B3ZsgScr) control cells were, as expected, highly positive for anti-PD-1 staining. In PD-
1-deficent B3Z cells (B3ZsgPdcd1) only dead cell marker-positive cells stained positive 
for PD-1 (Fig. 8E).  
 
Together, the data show that the anti-PD-1 antibody clone 29F1A12 specifically 
recognizes PD-1 in viable cells but binds additionally to an unknown antigen in dead 
cells.  
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Figure 8: Anti-PD-1 antibody 29F1A12 binds to an unknown antigen in dead cells 
Anti-PD-1 staining of splenic MDSC was analyzed by flow cytometry. Fixable viability dye (FVD) 
(A), caspase 8 activity (aCasp8) and 7-AAD (B) were used to identify dead or dying cells. 
Proportion of PD-1+ MDSC was quantified by flow cytometry (C). Splenocytes from wild-type and 
PD-1-deficient mice were cultured in the presence or absence of anti-CD3/anti-CD28 beads and 
anti-PD-1 staining was analyzed by flow cytometry (D). Wild-type and PD-1-deficient B3Z cells 
were treated with staurosporine or left untreated. Anti-PD-1 staining was measured by flow 
cytometry (E) A, B, E). One out of three independent experiments is shown.  
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3.3 Bone marrow model to study MDSC differentiation and 
function in vitro 
3.3.1. Tumor-derived factors induce expansion of MDSC-like cells in vitro 
Myeloid precursor cell can be isolated from the bone marrow and cultured in the 
presence of GM-CSF to generate bone marrow-derived DC (BMDC) [122]. To study the 
influence of tumor-derived factors on myeloid precursor cells in vitro, GM-CSF-stimulated 
bone marrow cell cultures were cultivated in the presence and absence of tumor-
conditioned medium (CM) generated from different KPC-derived pancreatic tumor cell 
lines (Fig. 9A). 
 
MDSC-like4 cell frequency was elevated in the presence of tumor CM. In contrast, BMDC 
frequency was reduced. Some CM induced a more M-MDSC-pronounced phenotype 
(e.g. 13871), whereas other CM favored the differentiation of PMN-MDSC-like cells (e.g. 
8025, 8661) (Fig. 9B, C). Both GM-CSF and G-CSF were secreted by most of the KPC-
derived tumor cell lines (Fig. 9D). Interestingly, the two cell lines, 8025 and 8661, with 
the highest G-CSF secretion induced the highest PMN-MDSC-like cell expansion in vitro. 
PMN-MDSC-like cell frequency correlated with the G-CSF concentration in the 
conditioned medium of the different tumor cell lines (p = 0.0006, R² = 0.746), whereas 
BMDC frequency correlated inversely (p = 0.01, R² = 0.577) (Fig. 9E).  
  
                                               
4 In vitro generated suppressive myeloid cells are not as clearly defined as MDSC in vivo. Therefore, in this 
study in vitro generated bone marrow-derived suppressive myeloid cells are called MDSC-like cells. PMN-
MDSC and PMN-MDSC-like as well as M-MDSC and M-MDSC-like cells are defined by the same surface 
markers using flow cytometry. 
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Figure 9: Tumor-derived factors increase MDSC-like cell frequency in bone 
marrow culture. (continued) 
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Figure 9: Tumor-derived factors increase MDSC-like cell frequency in bone 
marrow culture. 
Bone marrow cells from C57BL/6 mice were cultured for 7 days in medium supplemented with 
GM-CSF and tumor-conditioned medium (CM) derived from pancreatic cancer cell lines (A). After 
7 days, cells were analyzed by flow cytometry (B, C). Cytokine concentration in CM was measured 
by ELISA (D). G-CSF concentration in CM was correlated to MDSC and BMDC frequency in bone 
marrow culture (E). 7-days cultured bone marrow cells were co-cultured with CFSE-labeled T 
cells and the proportion of proliferated CFSElow CD8+ and CD4+ T cells was analyzed by flow 
cytometry (F). After 7 days in culture, MHC-IIlow Gr1high (G) and MHC-IIhigh Gr1low (H) cells were 
sorted by FACS and co-cultured with CFSE-labeled T cells. T cell proliferation was monitored. 
Statistical analysis was performed using spearman correlation (E). Representative graphs of two 
independent experiments with n=2, error bar represent mean +/- SD. n.d. not detectable. 
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3.3.2. Tumor-derived factors induce suppressive capacity of MDSC-like cells 
To investigate the suppressive capacity of in vitro generated MDSC-like cells, cells from 
whole bone marrow cultures were co-cultured with anti-CD3/anti-CD28 beads-stimulated 
T cells. Bone marrow cells that were differentiated in the presence of tumor CM had a 
higher CD4+ and CD8+ T cell suppressive capacity as compared to controls (Fig. 9F).  
 
As the frequency and composition of MDSC-like cells differs depending on the tumor-
derived factors, Gr1highMHC-IIlow MDSC-like cells were isolated by FACsorting. As a 
control Gr1low MHC-IIhigh BMDC were isolated. As expected, MDSC-like cells had a higher 
suppressive capacity as compared to BMDC controls. MDSC-like cells cultured with 
T110299 CM showed the highest suppressive capacity (Fig. 9G, H). 
 
In summary, GM-CSF-driven bone marrow culture recapitulates MDSC development 
and the suppression phenotype in vitro. Tumor-derived factors, such as G-CSF expand 
PMN-MDSC-like cells and induce a suppressive program in MDSC-like cells.  
 
3.4 Therapeutic reprograming of MDSC via MDA5-based 
immunotherapy 
RIG-I-like helicases (RLH) such as MDA5 and RIG-I are promising targets for the 
immunotherapy of pancreatic cancer as they induce immunogenic tumor cell death and 
activate the immune system [46, 47]. Little is known about the effect of the MDA5 ligand 
poly(I:C) on MDSC. As PMN-MDSC are highly enriched in T110299 tumor-bearing mice, 
the effect of systemic poly(I:C) treatment on MDSC was investigated.  
 
3.4.1 Therapy with poly(I:C)c activates immune cells  
KPC-derived T110299 tumors were induced orthotopically in C57BL/6 mice; 18 and 20 
days later mice were treated with 50 µg poly(I:C) complexed with polyethylenimine (PEI) 
(poly(I:C)c) intravenously (Fig. 10A). Poly(I:C)c treatment induced a significant reduction 
of the tumor weight (p < 0.01; Fig. 10B). PMN-MDSC frequency was reduced by the 
treatment. In contrast, the M-MDSC frequency increased in both tumor (p < 0.01) und 
spleen (p < 0.05) after two treatments (Fig. 10C and Fig. 13D). In the spleen, poly(I:C)c 
treatment induced MHC class I expression on both MDSC populations. A similar 
induction was seen for PMN-MDSC in the tumor microenvironment. In contrast, the 
expression of MHC class I of M-MDSC was already elevated in the tumor prior to therapy 
and no further induction was measured (Fig. 10D). Similarly, PD-L1 expression on 
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MDSC in the spleen was induced upon poly(I:C)c treatment. As shown before, PD-L1 
levels of MDSC in tumor are elevated and no further induction was seen (Fig. 10E). 
 
No significant change in the frequency of CD4+ and CD8+ T cells was observed in both 
spleen and tumor (Fig. 10F, G). However, expression of the early activation marker 
CD69 was significantly increased in both T cell subsets in both tumor and spleen 
(Fig. 10F, G). The frequency of PD-1-expressing T cells was not influenced by the 
treatment at this time point (Fig. 10H).  
 
Figure 10: MDA5-targeted immunotherapy induces immune cell activation and 
tumor regression in PDAC-bearing mice (continued) 
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Figure 10: MDA5-targeted immunotherapy induces immune cell activation and 
tumor regression in PDAC-bearing mice 
KPC-derived T110299 tumors were implanted orthotopically. After 18 and 20 days mice were 
treated with 50 µg of poly(I:C)c intravenously (A). After 21 days, tumor weight (B) was measured 
and immune cells were analyzed by flow cytometry (C-H). Differences between control and 
poly(I:C)c treatment was analyzed using Mann Whitney U test, error bars represent mean +/- SEM 
of n = 6, asterisks indicate * p < 0.05, ** p < 0.01, *** p < 0.001. 
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3.4.2 MDA5-targeted immunotherapy reduces suppressive capacity of MDSC 
Next, the functional consequences of the poly(I:C)c treatment on MDSC was evaluated. 
Mice with PDAC were treated on day 18 and 20 after tumor implantation with poly(I:C)c, 
MDSC were isolated from the spleens and tumors on day 21 and T cell suppressive 
capacity was assessed (Fig. 10A). As shown before, tumor-derived MDSC were more 
suppressive compared to splenic counterparts. Importantly, poly(I:C)c treatment reduced 
the suppressive capacity of both PMN-MDSC and M-MDSC from tumor as well as the 
spleen (Fig. 11). 
 
Figure 11: MDA5-targeted therapy reduces suppressive capacity of MDSC. 
Mice were treated as shown in Fig. 10 A. After 21 days, MDSC were isolated, co-cultured with 
CFSE-labeled T cells and the proportion of proliferated CFSElow CD8+ (A) and CD4+ (B) T cells 
was analyzed by flow cytometry. Representative graphs of two independent experiments are 
depicted, error bars represent mean +/- SEM of duplicates. 
 
3.4.3 MDA5-targeted immunotherapy reprograms MDSC  
To investigate the effects of poly(I:C)c treatment on MDSC in more depth, unbiased 
whole transcriptome analysis was performed. Mice with orthotopic PDAC were treated 
on day 18 and 20 after tumor implantation with poly(I:C)c or were left untreated (Fig. 10A). 
On day 21, MDSC were isolated followed by RNA extraction and next-generation 
sequencing. In all poly(I:C)c treated mice, CXCL10 levels in the serum were elevated 
after the first and second treatment, indicating good treatment response. In the spleen, 
MDSC purity was on average 96.8% (SD = +/- 3.7%) and in the tumor the purity was on 
average 93.1% (SD = +/- 6.3). RNA yield ranged from 6.8 ng to 353.8 ng. Ribosomal 
RNA integrity was studied by Bioanalyzer 2100 and found adequate, as indicated by a 
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RIN value above 7 (Fig. S3). Tumor cell contamination in the MDSC samples was 
evaluated by measuring the expression of tumor cell-restricted genes such as cytokeratin 
8, 18 and 19. As expected, there was no tumor cell contamination in splenic MDSC. The 
concentration of tumor cell-restricted RNA was <1% and equally distributed in MDSC 
samples, indicating low tumor cell contamination (Fig. S3).  
 
First, an unbiased principle component analysis (PCA) using the 20.000 most expressed 
genes was performed. For both PMN-MDSC and M-MDSC, the replicates of each 
condition clustered closely, confirming the high quality of the data. For both MDSC types, 
PCA revealed that the first principle component (PC1) distinguishes the samples based 
on the compartment from which they were isolated. In PMN-MDSC 35.5% (PC1) of the 
variance between all samples contributed to the separation between spleen and tumor. 
In M-MDSC 20.4% of the variance could be attributed to the compartment where the 
cells were isolated from. The second principle component describes the changes that 
were induced by the poly(I:C)c treatment (PC2 9.5% and 14.4% for PMN-MDSC and M-
MDSC, respectively) (Fig. 12A).  
 
Next, the treatment-induced transcriptomic changes were analyzed by performing a 
differential gene expression analysis. As the change in suppressive capacity after 
poly(I:C)c treatment was observed in both spleen and tumor, genes were selected that 
were significantly differentially expressed in both organs (adjusted p < 0.05, 
fold change > 2). As shown in Fig. 12B, 116 genes were differentially expressed in 
PMN-MDSC from both compartments. In M-MDSC 134 genes were differentially 
expressed in both spleen and tumor. Functional annotation analysis using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) was performed with 
differentially expressed genes from both spleen and tumor. Genes were found to be 
significantly enriched in gene ontology biological process (GO:BP) clusters related to 
immune system processes, virus and type I IFN response-related pathways as well as 
to antigen presentation gene sets (Fig. 12C).  
 
The expression levels of the genes contributing to the functional annotation analysis from 
the spleen are depicted in Fig. 12D. Antigen presentation-associated genes of the H2 
complex and viral sensors such as genes of the 2'-5'-oligoadenylate synthetase (OAS) 
and IFN-induced protein with tetratricopeptide repeats (IFIT) family were enriched. 
Interestingly, one of the GO:BP terms in M-MDSC was embryonic hematopoiesis with 
Runx1, Pbx1 and Ahr being down-regulated upon poly(I:C)c treatment (Fig. 12D). The 
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expression levels of the genes contributing to the functional annotation analysis from 
both spleen and tumor are depicted in Fig. S4. 
 
Figure 12: MDA5-targeted immunotherapy induces a type I IFN-dominated 
reprograming of MDSC. 
Results 46 
 
Figure 12: MDA5-targeted immunotherapy induces a type I IFN-dominated 
reprograming of MDSC. 
Mice were treated as shown in Fig. 10A. After 21 days, MDSC were isolated and the transcriptome 
was analyzed by RNA sequencing. A) Unbiased principal component analysis (PCA) of the 
20.000 most expressed genes was performed. B) Number of differentially expressed genes in 
spleens and tumors from poly(I:C)c treated or untreated mice are depicted in a Venn diagram. C) 
DAVID functional gene annotation using the gene ontology biological processes (GO:BP) terms 
was performed. Significantly enriched GO:BP terms (adjusted p < 0.05) are depicted (C). 
Expression level of shared genes contributing to one of the GO:BP terms are shown in a heat 
map (D).  
 
3.4.4 Immune activation induced by MDA5-targeted therapy is IFNAR-mediated 
Poly(I:C)c treatment is known to induce a type I IFN response and the transcriptomic 
profile of MDSC in treated mice confirmed a predominant type I IFN response. Therefore, 
the role of type I IFN signaling upon poly(I:C)c treatment in MDSC was assessed using 
type I IFN receptor (IFNAR)-deficient mice. As shown in Fig. 13A, the same approach as 
before was used to investigate the role of type I IFN signaling. 
 
In line with previous data, tumor weight was significantly decreased in wild-type mice 
after poly(I:C)c treatment (p < 0.05). No significant difference in tumor weight was 
observed in IFNAR-deficient mice, supporting the role of type I IFN in the anti-tumor 
effect (Fig. 13B). Both wild-type and IFNAR-deficient mice secreted similar levels of 
CXCL10 upon poly(I:C)c treatment. In wild-type mice serum IL-6 levels were significantly 
elevated upon poly(I:C)c treatment (p < 0.01). In contrast, there was no significant IL-6 
induction upon poly(I:C)c treatment in Ifnar-/- mice, placing IL-6 production downstream 
of IFN signaling (Fig. 13C).  
 
Poly(I:C)c treatment led to a significant decrease of PMN-MDSC and an increase of 
M-MDSC frequency in the spleen of wild-type mice (p < 0.01). However, there was no 
significant change in the frequency of PMN-MDSC or M-MDSC in Ifnar-/- mice (Fig. 13D). 
In contrast to wild-type mice, there was no induction of MHC class I or PD-L1 upon 
poly(I:C)c treatment in splenic MDSC of Ifnar-/- mice, pointing towards a critical role of 
type I IFN in MDA5-based therapy induced changes in MDSC numbers and phenotype 
(Fig. 13E, F). 
 
Next, influence of MDA5-based therapy on the T cell frequency and expression of the 
activation marker CD69 was assessed. CD4+ and CD8+ T cell frequency in spleen and 
tumor was neither influenced by the genotype nor the treatment (Fig. 13G, H). As 
observed earlier, in wild-type mice poly(I:C)c treatment induced upregulation of CD69 
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expression in T cells. However, no significant increase of CD69 expression was found in 
CD4+ or CD8+ T cells in Ifnar-/- mice (Fig. 13H-J).  
 
Next, the role of type I IFN signaling on suppressive capacity of MDSC was investigated. 
Interestingly, under steady state conditions the suppressive capacity of MDSC in Ifnar-/- 
mice was reduced (Fig. 13K, L). This points towards a role of tumor-intrinsic type I IFN 
in MDSC differentiation in PDAC. As seen before, T cell suppressive capacity of both 
MDSC subtypes was reduced upon poly(I:C)c treatment in wild-type mice. The 
suppressive capacity of both PMN-MDSC and M-MDSC of Ifnar-/- mice was not reduced 
upon poly(I:C)c treatment as seen in wild-type mice, rather a small increase was 
observed (Fig. 13K, L). Together these data argue for a dual role of type I IFN signaling 
on MDSC suppressive capacity, a suppression promoting effect in tumors under “steady 
state” and an inhibitory effect upon massive MDA5-induced IFN production. 
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Figure 13: Treatment efficacy and immune activation of MDA5-based 
immunotherapy is mediated by type I IFN signaling. (continued) 
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Figure 13: Treatment efficacy and immune activation of MDA5-targeted 
immunotherapy is mediated by type I IFN signaling. 
A) KPC-derived T110299 tumors were implanted orthotopically in C57BL/6 wild-type and Ifnar-/- 
mice. After 18 and 20 days mice were treated with 50 µg poly(I:C)c intravenously. After 21 days, 
tumor weight (B) and serum levels of cytokines (C) were measured. Immune cells were analyzed 
by flow cytometry (C-F, H-I). MDSC were isolated, co-cultured with CFSE-labeled T cells and 
proportion of proliferated CFSElow CD4 and CD8 T cells was analyzed by flow cytometry (K, L). 
A-I) Differences mediated by genotype and treatment were statistically analyzed using a 2-way 
ANOVA followed by a post hoc test between the two treatment groups (B-F, H-I). P values of 2-
way ANOVA are reported in tables G and J. Results of post hoc tests are shown in each graph. 
K, L) Representative graphs of three independent experiments are depicted, error bars represent 
mean +/- SEM of duplicates. Asterisks indicate * p < 0.05, ** p < 0.01, *** p < 0.001. 
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3.4.5 MDSC are not capable of MHC class I antigen cross-presentation 
In addition to IFN response, the second significantly enriched functional gene cluster in 
the RNA-Seq experiment was associated with MHC class I antigen presentation. The 
majority of genes annotated in the KEGG pathway of MHC class I-dependent antigen 
processing and presentation are up-regulated in both PMN-MDSC (Fig 14A) and 
M-MDSC (Fig 14B) upon poly(I:C)c treatment. To investigate the antigen processing and 
presentation capability of MDSC, T110299 tumors expressing the model non-self antigen 
ovalbumin (OVA) were used. 18 and 20 days after tumor induction mice were treated 
with poly(I:C)c or were left untreated and MDSC from both tumor and spleen were 
isolated. Tumor-derived MDSC were co-cultured with OT-I T cells that uniformly express 
a T cell receptor specific for the MHC class I-restricted OVA peptide SIINFEKL and T 
cell proliferation was measured (Fig. 14C). Both MDSC types were unable to induce 
antigen-dependent CD8 T cell proliferation independent of treatment (Fig. 14D).  
 
As the amount of OVA antigen may be limiting in vivo, we also evaluated the capability 
of MDSC to process and cross-present OVA protein ex vivo. Splenic MDSC were 
isolated from T110299-OVA tumor-bearing hosts that were treated as described above. 
MDSC were incubated overnight with OVA protein and subsequently co-cultured with 
OT-I T cells. Again, no increase of T cell proliferation was measurable after 72 h of co-
culture with OVA-treated MDSC, independent of in vivo poly(I:C)c treatment (Fig. 14E).  
 
To rule out that lack of cross-presentation is due to T cell inhibition by MDSC, the 
presentation of exogenously pulsed peptide was assessed. MDSC from T110299-OVA 
tumor bearing hosts with and without prior poly(I:C)c treatment were isolated, MHC-I 
molecules were loaded with SIINFEKL peptides in vitro, washed and subsequently co-
cultured with OT-I T cells. Peptide-loaded MDSC were able to induce vigorous OT-I T cell 
proliferation. No differences were observed between MDSC of untreated or poly(I:C)c 
treated mice (Fig. 14F). Together, these data argue for a cross-presentation defect in 
MDSC populations that cannot be reverted by MDA5-based immunotherapy. 
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Figure 14: MDSC in mice with PDAC do not cross-present antigen to CD8 T cells. 
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Figure 14: MDSC in mice with PDAC do not cross-present antigen to CD8 T cells. 
RNA-Seq revealed induction of genes associated with MHC-I pathway upon poly(I:C)c treatment. 
Genes annotated in KEGG MHC-I pathway are depicted for PMN-MDSC (A) and M-MDSC (B). 
Genes that are up-regulated and down-regulated upon poly(I:C)c treatment are shown in green 
and red, respectively (A,B). T110299-OVA tumors were implanted orthotopically in C57BL/6 mice. 
After 18 and 20 days mice were treated with poly(I:C)c (C). After 21 days, MDSC were isolated 
from tumor (D) and spleen (E, F). Tumor-derived MDSC were not manipulated in vitro (D). Splenic 
MDSC were either incubated over night with OVA protein (E) or were loaded with the SIINFEKL 
peptide (F). MDSC were co-cultured with CFSE-labeled TCR-transgenic OT-I T cells and the 
proportion of proliferated CFSElow T cells was analyzed by flow cytometry (D-F). Representative 
graphs of two independent experiments are depicted, error bars represent mean +/- SEM of 
duplicates N/A = not analyzed. 
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3.5 Role of IRF4 in MDSC development and function 
3.5.1 IRF4 is expressed by M-MDSC, but not by PMN-MDSC  
Transcription factor IRF4 has been implicated to control macrophage M2 polarization 
and MDSC function [103, 104]. To study the role of IRF4 in MDSC in murine PDAC, IRF4 
expression of PMN-MDSC as well as M-MDSC was analyzed in tumor-free and tumor-
bearing mice by flow cytometry. IRF4 was expressed homogenously by M-MDSC in the 
blood, spleen and tumor independent of the tumor status. In contrast, IRF4 expression 
by PMN-MDSC in blood, spleen and tumor was close to the detection limit or absent 
(Fig. 15A, B). 
 
Next, IRF4 expression of myeloid cells in the bone marrow culture was evaluated in vitro. 
IL-4 and IL-13 are known inducers of IRF4 [90]. CD11b+ CD11c+ BMDC expressed IRF4 
and the expression could be further increased by stimulation with IL-4 and IL-13. IRF4 
expression in PMN-MDSC-like cells and M-MDSC-like cells was low. IL-4 and IL-13 
increased the expression of IRF4 in M-MDSC-like cells only (Fig. 15C).  
 
3.5.2 IRF4 deficiency increases MDSC-like cell frequency in vitro 
To evaluate the role of IRF4 in development and function of myeloid cells, bone marrow 
cells of wild-type and Irf4-/-mice were cultured for seven days in the presence of GM-CSF 
and T cell suppressive capacity was measured. IRF4-deficient cells suppressed the 
T cell proliferation more potently compared to WT controls (Fig. 15D).  
 
Next, the cellular composition of the bone marrow cultures was analyzed. The absolute 
cell count per culture dish as well as the relative frequency of MDSC-like cells was 
significantly increased in bone marrow cultures from Irf4-/- mice. The frequency of BMDC 
was significantly reduced and mature BMDC (CD11b+CD11c+MHC-IIhigh) were almost 
absent in cultures of Irf4-/-mice (Fig. 15E). Thus, IRF4 controls proliferation and 
differentiation of MDSC-like cells from bone marrow precursors. As the difference in 
MDSC composition in the cultures may influence the outcome of the suppressive effect 
in T cell suppression assays, FACSorted Gr1highMHC-IIlow MDSC-like cells from wild-type 
and Irf4-/- mice were co-cultured with T cells in the presence of anti-CD3/anti-CD28 
beads and T cell proliferation was measured. There was no significant difference in the 
T cell suppressive capacity of IRF4-deficient Gr1+ MDSC-like cells compared to wild-type 
controls, arguing against a direct role of IRF4 in controlling the suppressive mechanism 
of MDSC-like cells (Fig. 15F). 
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Figure 15: IRF4 deficiency leads to MDSC-like cell expansion in bone marrow 
cultures in vitro but does not influence their T cell suppressive function.   
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Figure 15: IRF4 deficiency leads to MDSC-like cell expansion in bone marrow 
cultures in vitro but does not influence their T cell suppressive function. 
IRF4 expression of MDSC subsets from tumor-free and PDAC-bearing mice was analyzed by 
flow cytometry (A-B). IRF4 expression of myeloid cells from bone marrow cultures were analyzed 
by flow cytometry in the absence and presence of IL-4 and IL-13 (C). Bone marrow cells from 
wild-type (WT) and Irf4-/- mice were co-cultured with CFSE-labeled T cells and proportion of 
proliferated CFSElow CD8+ and CD4+ (D) T cells was analyzed by flow cytometry. Absolute number 
of cells was counted, and relative cell frequency was analyzed by flow cytometry (E). Gr1high MHC-
IIlow cell population of WT and IRF4-deficient bone marrow cultures were FACSorted, co-cultured 
with CFSE-labeled T cells and the proportion of proliferated CFSElow CD8+ and CD4+ was 
determined (F). The difference between genotypes was statistically analyzed using Mann Whitney 
U test, error bars represent mean +/- SEM (n=3), asterisks indicate * p < 0.05, ** p < 0.01 and *** 
p < 0.001. 
 
3.5.3 Global IRF4 deficiency accelerates PDAC tumor growth 
To study the role of IRF4 in vivo, KPC-derived T110299 tumors were induced 
orthotopically in Irf4-/- mice. Three weeks after tumor induction, tumor weight in Irf4-/- mice 
was significantly increased compared to wild-type controls (Fig. 16A). Moreover, the 
survival of tumor-bearing Irf4-/- mice was significantly reduced (Fig. 16B). In both blood 
and spleen of Irf4-/- mice, PMN-MDSC frequency was significantly increased, with no 
significant change in the tumor (Fig. 16C). Similarly, M-MDSC frequency was 
significantly increased in the blood and spleen of Irf4-/- mice. There was no significant 
change in M-MDSC frequency in the tumor (Fig. 16D).  
 
As the MDSC frequency depends on tumor weight (Fig. 6D) and both MDSC frequency 
and tumor weight were elevated in Irf4-/- mice, MDSC frequency was correlated to the 
tumor weight for both genotypes separately (Fig. S5). As observed before in wild-type 
mice, there was a good correlation of tumor size and MDSC frequency in blood and 
spleen. Thus, accelerated tumor growth may determine the MDSC phenotype observed 
in Irf4-/- mice. 
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Figure 16: IRF4 deficiency accelerates PDAC tumor growth and expansion of 
MDSC populations in blood and spleen. 
T110299-derived PDAC were induced orthotopically in Irf4-/- and wild-type (WT) mice. After 21 
days, tumor weight was measured (A) and MDSC cell frequency in blood, spleen and tumor was 
analyzed by flow cytometry (C, D). Survival of orthotopic PDAC-bearing mice was monitored (B). 
Differences between genotypes were statically analyzed using the Mann Whitney U test (A, C, D) 
or Log rank test (B). Shown are pooled data from 2-3 independent experiments, error bars 
represent mean +/- SEM (n=5-8 mice/group), asterisks indicate * p < 0.05, ** p < 0.01, *** p < 
0.001. 
 
3.5.5  MDSC from IRF4-deficient mice show higher T cell suppressive capacity 
To study the functional consequences of IRF4 deficiency on myeloid cells, PDAC were 
induced in both Irf4-/- and wild-type mice. Three weeks later MDSC were isolated from 
the spleen, co-cultured with T cells and T cell proliferation was measured. PMN-MDSC 
as well as M-MDSC from Irf4-/- mice showed a higher suppressive capacity compared to 
wild-type controls (Fig. 17).  
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Figure 17: MDSC from IRF4-deficient mice have higher suppressive capacity 21 
days after tumor induction. 
T110299 tumors were induced orthotopically in Irf4-/- and wild-type (WT) mice. After 21 days, 
MDSC populations were isolated from the spleen, co-cultured with CFSE-labeled T cells and 
proportion of proliferated CFSElow T cells was analyzed by flow cytometry (A). Representative 
graphs of three independent experiments are shown, error bars represent mean +/- SEM (n=3). 
 
3.5.6 Myeloid-specific depletion of IRF4 accelerates PDAC growth 
IRF4 is expressed by many cells of the immune system, including T cells, B cells and 
DC. To study the intrinsic role of IRF4 solely in myeloid cells, two conditional mouse 
models were established. Ly6GCre mice, in which floxed target sites are specifically 
deleted in polymorphonuclear cells (including PMN-MDSC) [123], and LysMCre mice, in 
which floxed target sites are specifically deleted in granulocytes, monocytes, 
macrophages and partly DC (including PMN-MDSC and M-MDSC) [124], were cross-
bred with Irf4flox mice. Irf4flox mice were designed to express GFP instead of IRF4 upon 
successful Cre recombination under the same physiological control as IRF4. Therefore, 
the conditional IRF4 knockout mice can be used as reporter mice. First, expression of 
GFP was confirmed by flow cytometry. As expected, M-MDSC of the LysMCreIrf4fl/fl mice 
were positive for GFP in the blood, spleen and tumor. There was no GFP detectable in 
PMN-MDSC as well as M-MDSC of the Ly6GCreIrf4fl/fl mice (green, Fig. 18A). In contrast, 
in LysMCreIrf4fl/fl mice there was a small fraction of approximately 15 % of PMN-MDSC in 
blood, spleen and tumor that were positive for GFP (Fig. 18A). 
 
Next, the impact of myeloid-targeted IRF4 deficiency on PDAC tumor growth was 
investigated. KPC-derived T110299 tumors were orthotopically induced in Ly6GCreIrf4fl/fl 
mice, LysMCreIrf4fl/fl mice as well as Irf4fl/fl control mice. There was no significant 
difference between Ly6GCreIrf4fl/fl and control mice. In contrast, tumor weight was 
significantly increased in LysMCreIrf4fl/fl mice compared to IRF4fl/fl control mice (Fig. 18B). 
For both myeloid-specific IRF4-deficient mice, there was no survival disadvantage 
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compared to Irf4fl/fl controls (Fig. 18C). Three weeks after tumor induction MDSC 
frequencies were analyzed by flow cytometry. There was no significant difference in 
PMN-MDSC in blood, spleen and tumor of LysMCre-Irf4fl/fl mice and Ly6GCreIrf4fl/fl mice 
compared to Irf4fl/fl controls. M-MDSC frequency was significantly increased in the spleen 
of LysMCreIrf4fl/fl mice. However, no difference in M-MDSC frequency was detectable in 
the blood or tumor of the myeloid cell-specific IRF4-deficient mice (Fig. 18D).  
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Figure 18: Targeted deletion of Irf4 in LysMCre but not Ly6GCre mice increases 
tumor growth but has no influence on survival.  
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Figure 18: Targeted deletion of Irf4 in LysMCre but not Ly6GCre mice increases 
tumor growth but has no influence on survival. 
KPC-derived T110299 tumors were induced orthotopically in Ly6GCre Irf4fl/fl (green), LysMCre 
Irf4fl/fl (blue) and Irf4fl/fl (black) mice. After 21 days, GFP expression of MDSC was analyzed by 
flow cytometry (A), tumor weight was measured (B) and MDSC frequency was analyzed by flow 
cytometry (D). Survival of PDAC-bearing mice was monitored (C). Statistical analysis was 
performed using Kruskal Wallis test, followed by Dunn’s multiple comparisons test between 
controls and conditional knock-out mice. Pooled data from 3 independent experiments are 
depicted, error bars represent mean +/- SEM (n=8-14 mice/group), p value of Dunn’s test are 
shown in the graph, asterisks indicate * p < 0.05. 
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4. Discussion 
4.1 PDAC induce an immunosuppressive program in myeloid 
cells 
In the first part of the study, the immune cell composition in the KPC-derived T110299 
tumor model was characterized. We found that in PDAC-bearing hosts the myeloid 
compartment in blood, lymphoid organs and tumor is expanded and an 
immunosuppressive program is induced. Similar findings could be recapitulated in vitro 
using a bone marrow culture system. 
 
In the first three weeks of tumor growth, the relative intratumoral immune cell composition 
changed and three waves of different immune cell infiltrates could be described: One 
week after tumor induction, innate immune cells such as NK cells and Ly6C+ monocytes 
were the dominant cell type. After two weeks, the tumor stroma was dominated by CD8+ 
and CD4+ T lymphocytes. After three weeks, the relative frequency of T cells dropped 
and PMN-MDSC were significantly enriched. This situation closely mirrors the human 
situation, as myeloid cells typically densely infiltrate human PDAC tissue and T cells are 
rarely found [36]. Therefore, knowledge of the intratumoral immune cell composition is 
important when investigating immunotherapy in orthotopic PDAC models. The tumor 
microenvironment of advanced tumors around day 21 reflects the human situation best, 
however, experimental treatments in transplantable tumor models commonly start 
between day 5 and 10 [47]. In this early phase the tumor microenvironment is dominated 
by NK cells and T lymphocytes and thus may more easily respond to immunotherapy. 
For studying the role of poly(I:C)c on MDSC polarization and function in this study, mice 
were treated on day 18 and 20 and therefore, the immune cell composition should more 
closely mirror the human situation.  
 
We found that CD8+ T cells infiltrating T110299 tumors were strongly expressing the 
checkpoint molecule PD-1. Li et al. showed that the frequency of PD-1+ cells among 
CD8+ T cells in the tumor of KPC-derived models correlates with response to 
immunotherapy [20]. Therefore, the T110299 orthotopic tumor model is an interesting 
model for studying immunotherapy of PDAC. 
 
Both, G-CSF and GM-CSF are growth factors implicated in MDSC expansion in PDAC 
[118, 119]. We showed that GM-CSF was not detectable in the serum of T110299 tumor-
bearing mice. In contrast, G-CSF levels were highly elevated and correlated significantly 
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with PMN-MDSC frequency in blood and spleen. Furthermore, G-CSF levels secreted 
by different KPC-derived PDAC cell lines in vitro correlated with PMN-MDSC-like cell 
frequency in bone marrow cultures. Bayne et al. showed that GM-CSF levels are 
elevated in the tumor microenvironment of spontaneous KPC tumors. Furthermore, they 
showed that GM-CSF depletion reduced the recruitment of Gr1+ MDSC [118]. 
Interestingly, they did not report on GM-CSF levels in serum. Therefore, the role of GM-
CSF in inducing a systemic expansion of the myeloid compartment by acting on myeloid 
precursors in the bone marrow is not yet clear. Welte et al. showed that in breast cancer 
G-CSF regulates PMN-MDSC accumulation [125]. Li et al found that both CXCL1 and 
G-CSF are important regulators of MDSC recruitment in the tumor stroma in pancreatic 
cancer [20]. Both cytokines appear to be key hurdles for successful immunotherapy 
[126]. Further studies are needed to dissect the local and systemic role of GM-CSF and 
G-CSF in mice with PDAC. 
 
Myeloid cells in the orthotopic T110299 model fulfill all three criteria that have been 
defined recently by the leading scientists in the field to classify MDSC [18]: Firstly, the 
myeloid compartment is expanded in T110299-bearing mice and bone marrow cultures 
supplemented with tumor conditioned medium. Secondly, both PMN-MDSC 
(CD11b+Ly6G+Ly6Clow) and M-MDSC (CD11b+Ly6G-Ly6Chigh) express the surface 
markers for definition. Thirdly, both MDSC subtypes acquire T cell suppressive activity 
in tumor-bearing host or when cultured in the presence of tumor-conditioned medium 
[127]. The GM-CSF-driven bone marrow culture supplemented with tumor-conditioned 
medium resembles the characteristics of MDSC differentiation in vivo and could therefore 
be a valuable tool for studying MDSC differentiation and function in vitro.  
 
In humans, it has been shown that cancer patients bear distinct subsets of granulocytes 
and PMN-MDSC [63]. To date, no marker has been identified to distinguish PMN-MDSC 
from granulocytes in mice. In renal cell carcinoma more than 17 subtypes of TAMs have 
been proposed by mass cytometry [128]. Recent advances in high dimensional single 
cell analysis methods such as mass cytometry and single cell transcriptomic analysis 
(scRNA-Seq), will improve the understanding of myeloid subpopulations and will facilitate 
the identification of additional therapeutic targets of pro-tumoral and anti-tumoral myeloid 
cells.  
  
Discussion  63 
 
4.2 Anti-PD-1 antibodies cross-react with an unknown marker in 
dying cells  
In this study, we showed that the anti-PD-1 antibody clone 29F1A12 cross-reacts with 
an antigen in cell death marker-positive MDSC, CD4+ T cells and B3Z T cell hybridoma 
cells. In genetic deletion studies using primary cells as well as cell lines, we confirmed 
that this staining of dead cells with anti-PD-1 mAb is due to unspecific binding to an 
unknown intracellular antigen. In further experiments we were able to show that B16F10 
melanoma cells that were reported to express PD-1 [129] do not express PD-1, but 
instead the anti-PD-1 antibody stained a distinct nuclear antigen in dead cells, 
characterized by low forward scatter characteristic and positive staining with cell death 
dyes [130]. A similar staining pattern was observed with another anti-PD-1 antibody 
clone, namely RMP1-14 [130]. Thus, the antibody-binding epitopes of PD-1 and the 
unknown nuclear antigen seem to share similar motifs.  
 
This study is questioning the results of several other studies, describing PD-1 expression 
in non-T cells, such as MDSC and tumor cells [79, 129]. We conclude that flow cytometric 
data obtained with the anti-PD-1 antibody clones 29F1A12 and RMP1-14 have to be 
carefully analyzed. Small, death cell marker positive cells have to be strictly excluded to 
avoid false conclusions. 
 
4.3 MDA5-based immunotherapy reprograms MDSC in PDAC-
bearing mice 
In this study, we showed that MDA5-based immunotherapy with poly(I:C)c reprograms 
MDSC leading to a reduced suppressive capacity. In this respect, type I IFN appears to 
be the key driver of modulated MDSC function in vivo. MDA5 activation is known to 
induce a type I IFN driven immune response [47]. Whole transcriptome sequencing of 
poly(I:C)c treated MDSC and experiments with poly(I:C)c treated IFNAR-deficient mice 
confirmed the pivotal role of type I IFN in MDSC biology and the role in poly(I:C)c 
treatment. 
 
Here, we showed that poly(I:C)c treatment reduced the number of splenic PMN-MDSC 
whereas the M-MDSC frequency in spleen and tumor were increased upon treatment. 
The changes in immune cell frequency were strictly dependent on IFNAR signaling, as 
shown in IFNAR-deficient hosts. In line with these findings, Dangi et al. recently reported 
that CD11b+Ly6Chigh M-MDSC were increased whereas CD11b+Gr1high PMN-MDSC 
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were reduced in an acute type I IFN-driven virus infection model [131]. IFN- is reported 
to act on bone marrow myeloid progenitor cells to shift the development from granulocytic 
to monocytic cells [131]. This suggests that systemic RLH activation might interfere with 
the development of MDSC in the bone marrow. 
 
On both MDSC subtypes in spleen, activation markers such as MHC-I and PD-L1 were 
upregulated upon poly(I:C)c treatment. The induction was less pronounced in the tumor 
tissue. The upregulation of MHC-I and PD-L1 upon poly(I:C)c treatment was strictly 
dependent on type I IFN signaling, as demonstrated with IFNAR-deficient mice. Xiao et 
at. found that autocrine type I IFN stimulation through constant JAK-STAT signaling in 
MDSC induces the expression of PD-L1 [76]. Interestingly, in steady state PD-L1 
expression was not decreased in Ifnar-/- mice in the T110299 tumor model, arguing for 
other potential mechanisms leading to PD-L1 upregulation in intratumoral MDSC. 
Analysis of T cells in our model revealed induction of the early activation marker CD69 
in both CD4+ and CD8+ T cells, which was also type I IFN mediated. These findings are 
in line with previous reports [132].  
 
Importantly, we demonstrated that poly(I:C)c treatment reduced the suppressive capacity 
of both MDSC subtypes, suggesting that MDSC function may play a role in the anti-tumor 
effect of poly(I:C)c-based therapy, which has been shown to be CD8+ T cell-dependent 
[47]. In line with our data on poly(I:C)c treatment, Zoglmeier et al. showed that TLR9-
based therapy reduces PMN-MDSC frequency and diminishes the suppressive capacity 
of MDSC [133]. Type I IFN induction is a shared down-stream effect of both RLH and 
TLR9 signaling [134].  
 
Interestingly, the role of type I IFN signaling in the suppressive function of MDSC appears 
to have two opposing sides: The suppressive capacity of MDSC in Ifnar-/- mice was 
lower compared to wild-type controls, arguing for an important role of tumor 
autochthonous type I IFN in MDSC differentiation. Surprisingly, in contrast to wild-type 
mice, the suppressive capacity of MDSC in Ifnar-/- mice increased upon poly(I:C)c 
treatment from poor suppressors to moderate suppressors. These differences in the 
suppressive capacity point toward opposing roles of type I IFN, which cannot be 
separated in Ifnar-/- mice, as both effects are lacking. 1) Tumors including PDAC induce 
a chronic inflammation, which is accompanied by type I IFN production. It has been 
shown in other tumor models that DNA release by dying tumor cells triggers STING 
activation leading to a low-grade type I IFN induction [77]. 2) In contrast, poly(I:C)c 
treatment mimics an acute viral infection leading to high levels of type I IFN in a temporal 
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limited manner. Taleb et al. showed that chronic administration of recombinant IFN- at 
a dose characteristic for a chronic viral infection induced T cell suppressive activity in 
Ly6Chigh monocytes. In contrast, short high-dose treatment with IFN- - mimicking an 
acute viral infection - did not induce T cell suppressive potential in Ly6Chigh monocytes 
[135]. In this line, Zoglmeier et al. showed that high levels of recombinant IFN- is 
sufficient to reduce the immunosuppressive function of MDSC from C26 tumor bearing 
mice [133].  
 
Thus, based on our data and published reports, one can hypothesize that tumor 
autochthonous, low-dose type I IFN stimulation initiates a suppressive program in 
MDSC, which is particularly pronounced in the tumor microenvironment. In contrast, 
RLH-based therapy induces high-dose type I IFN, mimicking an acute viral infection, 
which leads to a reduction of suppressive capacity. RNA sequencing of untreated 
T110299 tumors could confirm upregulation of genes associated with a type I IFN 
response, when compared to normal pancreas (unpublished data). Recent analysis of 
human pancreatic resections identified a subtype of PDAC with a predominant type I IFN 
signature [136]. Further studies are needed to understand the functional status of MDSC 
from IFNAR-deficient hosts. This may provide further insights in type I IFN-independent 
mechanisms influencing the suppressive capacity of MDSC upon RLH-based 
immunotherapy. 
 
Whole transcriptome analysis revealed potential antigen cross-presentation function of 
MDSC, which has been described for professional antigen presenting cells such as DC 
in the context of RLH-based therapy [46]. Furthermore, Lee et al. demonstrated that 
MDSC isolated from 4T1 breast tumor-bearing mice can be differentiated in 
macrophages and DC in vitro using the TLR7/8 agonist resiquimod [137]. Spinetti et al 
showed in a TLR7-targeting therapy that MDSC upregulated antigen presenting markers 
in vivo and that bone marrow generated MDSC-like cells presented antigens on MHC-II 
and stimulated CD4+ T cell proliferation upon TLR7 activation [138]. In our model, MHC-
II was downregulated upon poly(I:C)c treatment whereas the MHC class I-dependent 
antigen processing and presentation machinery was upregulated on transcriptomic level. 
Furthermore, upregulation of MHC-I and the costimulatory molecule CD86 was 
confirmed on protein level by flow cytometry. This led us to investigate cross-presenting 
capacity of MDSC both in vitro and in vivo using the model antigen OVA. These 
experiments clearly showed that MDSC isolated from OVA-expressing T110299 tumor-
bearing hosts are unable to activate CD8+ OT-1 T cells, irrespective of treatment with 
poly(I:C)c or not. Furthermore, MDSC loaded ex vivo with OVA protein did not activate 
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OT-I T cells, indicative of lacking cross-presenting function. To rule out that lack of OT-I 
T cell stimulation was due to T cell suppression by MDSC, MHC-I molecules of MDSC 
were externally loaded with SIINFEKL peptide, which resulted in efficient OT-I T cell 
proliferation. Taken together, no evidence was found that MDSC can present tumor-
associated antigen in the T110299 tumor model, irrespective of poly(I:C)c treatment. 
Upregulation of MHC-I expression is more likely reflecting an indirect response to IFNAR 
signaling. 
 
Another gene set that was identified in the RNA-Seq experiment was the GO:BP term 
embryonic hematopoiesis, which was significantly enriched in M-MDSC. One of the 
genes contributing to enrichment is Runx1, a crucial regulator of early hematopoiesis 
[139]. Recently, RUNX1 has been linked to MDSC differentiation and function. 
Controversially, Tian et al. showed that gene silencing of RUNX1 increased the 
suppressive capacity of both PMN-MDSC and M-MDSC. However, according to our 
RNA-Seq data, Runx1 is down-regulated upon poly(I:C)c treatment, correlating with 
reduced suppressive activity. Further studies are needed to dissect the role of RUNX1 
in MDSC function in the setting of RLH-based immunotherapy [140].  
 
The precise mechanism of MDSC-mediated T cell suppression in the PDAC model was 
not addressed in this study. Several genes defined by Bronte et al. have been implicated 
to mediate suppressive capacity in MDSC, such as Arg1, Nos2, Cebpb, Pdl1 and 
S100a8/9 [18]. Of note, in the differential gene expression analysis between untreated 
and poly(I:C)c treated MDSC, none of these genes were significantly altered. 
 
CCL5 is a type I IFN-inducible gene that is upregulated upon poly(I:C)c treatment. In 
melanoma, MDSC are recruited to the tumor in a CCL5-CCR5-dependent manner. 
Therapeutic blockade of CCL5 in a melanoma mouse model reduced the migration of 
MDSC into the tumor and improved survival [141]. One can therefore speculate that 
CCL5 blockade is a potential combination partner for RLH ligands or in general 
type I IFN-inducing therapies. Another promising combination partner of RLH-targeting 
therapy is checkpoint blockade as PD-L1 expression is induced upon type I IFN signaling 
and intratumoral T cells are highly positive for PD-1. Current projects in our working 
group address this question in several murine tumor models. 
 
Taken together, these data suggest that RLH-based immunotherapy in the T110299 
PDAC model induces a systemic immune activation and a reprograming of MDSC 
leading to a reduction of their suppressive function. In this respect, type I IFN play an 
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important role in modulating MDSC function, similar to an acute viral infection. For many 
other treatment strategies in preclinical and clinical development type I IFN play an 
important role. For example, radiation therapy can induce type I IFN via the cGAS-STING 
pathway [142]. Moreover, oncolytic viruses, which are potent inducers of type I IFN, are 
currently investigated in clinical trials [143]. RLH ligands broaden the repertoire of potent 
type I IFN inducers leading to enhanced immune-mediated tumor control. RLH-based 
immunotherapy therefore holds promise to improve outcomes for patients with cancer 
[144]. 
 
4.4 IRF4 deficiency accelerates pancreatic tumor growth and 
expands MDSC 
During the course of this study, Nam et al reported that IRF4 is expressed by MDSC, 
particularly PMN-MDSC. Moreover, the group showed that IRF4-defciency increases 
MDSC frequency and induces suppressive function [104].  
 
In contrast to Nam et al., this study showed by anti-IRF4 antibody staining as well as 
using GFP reporter mice that IRF4 is not expressed by PMN-MDSC or granulocytes, but 
instead by M-MDSC. Nam et al. studied the role of IRF4 in two mouse models: the 
BALB/c-derived 4T1 breast cancer model and the C57BL/6-derived B16F10 melanoma 
model. However, expression data were only presented for BALB/c mice, whereas in this 
study C57BL/6 mice were used. The difference between Nam et al. and the findings of 
this study could possibly be explained by the usage of different mouse strains [104].  
 
As reported by Nam et al., IRF4 deficiency expands the frequency of MDSC-like cells in 
bone marrow cultures and increases the suppressive capacity of the whole bone marrow 
culture. The increase of MDSC-like cells in IRF4-deficient cultures could be confirmed in 
this study. However, the GM-CSF-driven culture contains, besides MDSC-like cells with 
suppressive capacity also BMDC which are less suppressive or even stimulatory in a 
mature stage. To study the suppressive activity of MDSC-like cells alone, MDSC-like 
cells were isolated from the bone marrow culture in this study. This strategy revealed 
that isolated MDSC-like cells do not differ in their suppressive capacity in wild-type and 
IRF4-deficient mice. These findings lead to the conclusion that in C57BL/6 mice IRF4 
deficiency increases the proportion of suppressive MDSC-like cells in vitro but does not 
influence their suppressive capacity. 
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GM-CSF-driven bone marrow cultures are a common model to generate DC in vitro, 
however, Helft et al. showed through comprehensive analysis that GM-CSF-driven bone 
marrow culture consists of a heterogeneous mix of myeloid cells. Generally, all 
CD11c+MHC-II+ cells are considered as BMDC. However, Helft et al. defined two distinct 
populations within the BMDC population: GM-macrophages (CD11c+MHCIIint 
CD115+MerTK+) and GM-dendritic cells (CD11c+MHC-IIhiCD115–CD135+) [122]. In IRF4-
deficient cultures, the frequency of CD11c+MHC-IIhigh dendritic cells was dramatically 
reduced indicating that GM-dendritic cells are the main population affected by IRF4. 
Vander Lugt et al. showed that IRF4-deficient dendritic cells failed to induce MHC-II-
dependent CD4+ T cell proliferation and that IRF4 regulates the MHC-II peptide loading 
machinery transcriptionally [145].  
 
Global deletion of IRF4 led to accelerated T110299 pancreatic tumor growth and reduced 
survival accompanied by a systemic increase of both PMN-MDSC and M-MDSC 
frequencies in the peripheral organs. Of note, selective IRF4 deletion in Ly6G+ cells had 
no effect on tumor growth, survival or MDSC frequency. This is in line with the above 
discussed expression data with lack of IRF4 expression in Ly6G+ cells. In contrast, 
myeloid deletion of IRF4 in the LysMCreIRF4flox mouse model led to increased tumor 
weight and M-MDSC frequency, but no significant change in survival.  
 
The role of IRF4 in myeloid cells is difficult to dissect. On the one hand, IRF4 deficiency 
increased the frequency of MDSC-like cells in vitro and led to a dramatic expansion of 
both MDSC subtypes in vivo. On the other hand, myeloid-specific depletion of IRF4 in 
vivo increased the frequency of M-MDSC in the spleen only, whereas PMN-MDSC 
frequency and M-MDSC frequency in the blood were not significantly altered. There are 
two possible explanations for this discrepancy: Firstly, IRF4 might regulate the 
differentiation of MDSC at an early progenitor state that is not yet sufficiently targeted in 
the LysMCre conditional mouse model. Lineage tracing experiments using the LysM-GFP 
reporter mice showed that LysM is already expressed in a proportion of hematopoietic 
stem cells. The Cre recombinase activity increased in the common myeloid precursor 
(CMP) and granulocyte-macrophage precursor (GMP) [146]. The targeting efficiency in 
macrophages and granulocytes is described to be almost 100% [124, 147]. However, in 
our model, the recombination efficiency for IRF4 in M-MDSC was on average only 
around 70% ranging from 30 to 90% (Fig. 18A).  
 
Secondly, the deletion of IRF4 in T cells, B cells and DC could contribute to the 
accelerated tumor growth and the reduced survival in global IRF4-deficient mice. 
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Although there is increasing evidence of regulatory function of B cells, the role of B cells 
in the murine pancreatic cancer model remains unclear [148]. IRF4 controls the function 
of cDC2 cells, however it is dispensable for cDC1 development and function. The role of 
cDC2 in tumor immunology is still a matter of debate. In contrast to cDC1, cDC2 are not 
required for the induction of antigen-specific T cell responses. There is increasing 
evidence that IRF4 is pivotal for an effective, sustained CD8+ T cell response. T110299 
tumor cells are susceptible to CD8+ T cell killing in vivo, and one could postulate that 
accelerated tumor growth in IRF4-deficient hosts is at least partially due to T cell 
dysfunction. As shown in Fig. 6I, PMN-MDSC frequency in tumor, blood and spleen, as 
well as M-MDSC frequency in the blood correlated with the tumor weight. Therefore, the 
increase in MDSC frequency in IRF4-deficient hosts could be a secondary effect due to 
the increased tumor size. The sample size in this study was too small to perform a 
regression analysis of the connection between tumor size and MDSC frequency 
depending on the genotype. However, preliminary correlation analysis suggests that 
tumor size has a greater influence on MDSC frequency than the IRF4 genotype (Fig. S5). 
Further studies are needed to dissect the role of IRF4 in different immune cell subsets. 
 
The suppressive activity of MDSC from IRF4-deficient mice was higher compared to wild-
type controls. This is in contrast to the suppressive capacity of in vitro generated MDSC-
like cells. Again, tumor size influences the suppressive capacity of MDSC. The inter-
assay variability makes it difficult to compare the absolute suppressive capacity of many 
samples. A correlation analysis of the tumor weight and the suppressive capacity is not 
feasible due to the low number of replicates. Further studies with comparable tumor sizes 
in both groups are required to better understand to role of IRF4 in the suppressive 
capacity of MDSC in vivo. 
 
Taken together, these data demonstrate that IRF4 plays an important role in the immune 
control of T110299 tumor development. Polymorphonuclear cells do not express IRF4 in 
T110299 tumor bearing mice and in line with that, deletion of IRF4 in Ly6G+ cells did not 
alter T110299 tumor development. In the in vitro bone marrow culture, the differentiation 
of MDSC-like cells from precursor cells was dramatically accelerated, but the 
suppressive capacity was not affected. The role of IRF4 in myeloid cells in vivo is still not 
fully understood and further studies are needed to dissect the role of IRF4 in immune 
cells in PDCA.  
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5. Summary 
Despite recent advances in the understanding of the molecular pathology and thereof 
resulting targeted therapies of PDAC, the prognosis of affected patients remains very 
poor, pointing out the need for developing new treatment modalities. Immunotherapy has 
shown remarkable success in several tumor types, however, immunotherapeutic 
approaches explored in patients with PDCA have shown no clinical benefit. A major 
hurdle for immunotherapy is the immunosuppressive tumor microenvironment with 
MDSC being a key component. The aim of this study was to characterize the immune 
cell composition in a murine PDCA model with a special focus on MDSC and to 
investigate the effect of RLH-based immunotherapy on the differentiation and function of 
MDSC. Additionally, the role of the transcription factor IRF4 in MDSC development and 
function was assessed. 
 
We found that MDSC frequency and suppressive capacity are significantly increased in 
PDAC tumor-bearing mice, accompanied by a decrease of infiltrating T cells. The 
expansion of MDSC and the induction of a suppressive program could be modeled in 
vitro using bone marrow cell cultures in the presence of tumor-derived factors. G-CSF 
was identified as a key factor driving the expansion of PMN-MDSC in vivo and in vitro. 
Additional tumor-derived factors enhance suppressive programming. 
 
The PD-1/PD-L1 axis has been identified as a potent tumor-induced immune 
suppressive mechanism. In contrast to previous reports, we could rule out PD-1 
expression by MDSC and several tumor cell lines tested. Commonly used anti-PD-1 
antibody clones were found to bind unspecifically to an intracellular antigen in dead cells. 
Using wild-type and PD-1 deficient cell lines clearly demonstrated that when dead cell 
exclusion is strictly applied, PD-1 expression is restricted to T cells in tumor-bearing 
hosts.  
 
Our group previously reported that RLH-based immunotherapy mediates a systemic type 
I IFN response, immunogenic cell death and effective T cell-mediated antitumor immunity 
[46, 47, 72]. In the present work systemic and intratumoral immune activation was further 
assessed with a special focus on MDSC. Treatment of PDAC tumor-bearing mice with 
the MDA5 ligand poly(I:C)c reduced PMN-MDSC frequency whereas M-MDSC frequency 
was increased. This effect was type I IFN-dependent. Interestingly, the suppressive 
capacity of MDSC in treated mice was strongly reduced. Whole transcriptomic profiling 
of isolated MDSC populations from spleen and tumor revealed functional reprograming. 
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Altered gene sets included type I IFN signaling and upregulation of genes associated 
with antigen presentation, such as MHC-I, B2m and CD86. However, functional assays 
did not detect MHC-I-restricted antigen presenting function in MDSC using an OVA-
expressing PDCA model, ruling out professional APC function in MDSC.  
 
IRF4 has been reported to play an important role in myelopoiesis, however the precise 
impact of IRF4 in MDSC in the context of PDAC has not been defined. The role of IRF4 
on MDSC populations in PDAC-bearing hosts was studied in global and conditional 
knockout mouse models that were generated for this study. IRF4 expression was only 
found in M-MDSC but not PMN-MDSC. In bone marrow cultures, IRF4 deficiency 
increased MDSC-like cell frequency, but the suppressive capacity of MDSC-like cells 
was not influenced. In vivo, global IRF4 deficiency accelerated PDAC tumor growth, 
which was associated with an increased MDSC frequency. Myeloid-specific deletion of 
IRF4 using Ly6G-Cre and LysM-Cre mice did not influence survival and the changes in 
MDSC frequency were less pronounced. Interestingly, the suppressive capacity of IRF4-
deficient MDSC from global knockout mice was increased three weeks after PDAC tumor 
induction, which is possibly linked to increased tumor size in these mice. Taken together, 
IRF4 deficiency accelerates myelopoiesis and MDSC differentiation in vitro and in vivo. 
Further studies are needed to unravel the role of IRF4 in the suppressive function. 
 
In summary, tumor-derived factors such as G-CSF induce emergency myelopoiesis in 
PDAC bearing hosts leading to enhanced MDSC numbers and T cell suppression. 
MDSC are promising targets for novel immune therapeutic interventions. RLH-based 
immunotherapy leads to functional reprograming of MDSC with reduced suppressive 
capacity, largely depending on type I IFN signaling. Drugs targeting MDSC development 
have the potential to improve anti-tumor immunotherapy.  
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7. Appendix 
7.1 Supplementary figures 
 
  
 
 
Figure S1: Gating strategy for flow cytometric analysis and FACSorting of splenic 
and tumor MDSC populations. 
Representative FACS plots of single cell suspensions generated from spleen and tumor. Arrows 
indicate which events were used for the subsequent gating strategy. 
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Figure S2: Gating strategy for flow cytometric analysis of different immune cell 
populations in tumor, spleen and blood. 
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Figure S3: Quality controls of RNA sequencing samples  
Mice were treated as shown in Fig. 5A. A) 6 hours after the first and 16 hours after the second 
poly(I:C)c treatment, CXCL10 concentration in serum was measured by ELISA. B) FACSorting 
purity of MDSC was analyzed by flow cytometry. RNA quantity, RNA quality and integrity after 
isolation was analyzed using Bioanalyzer. C) RNA purity was analyzed quantifying tumor-specific 
cytokeratin expression levels by qRT-PCR. T110299 tumor samples were used as positive 
controls. D) After library preparation for RNA sequencing, DNA concentration and length were 
analyzed using the Bioanalyzer, n=4/group.  
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Figure S4: Expression of genes contributing to one of the GO:BP terms  
Heatmap showing the expression of genes contributing to one of the GO:BP terms in both spleen 
and tumor of M-MDSC and PMN-MDSC. Samples were arranged unbiased using the Euclidean 
clustering. 
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Figure S5: Correlation of MDSC frequency with tumor weight in wild-type and  
Irf4-/- mice. 
Frequency of MDSC populations from spleen (A) and blood (B) were correlated with the tumor 
weight. 
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7.2 Abbreviations 
3-MCA 3-Methylcholanthrene 
4T1 Murine breast tumor model 
ACM Acinar-to-ductal metaplasia 
ADEX Aberrantly differentiated endocrine/exocrine subtype 
AID Activation-induced cytidine deaminase 
AF Alexa Fluor™ 
APC Antigen presenting cell  
ARG1 Arginase 1 
Blimp1 Protein gene coded by the Prdm1 gene 
BRCA Breast Cancer, early-onset 
BSA Bovine Serum-Albumin 
C57BL/6 Inbred mouse strain  
CAF Cancer-associated fibroblasts 
CCL CC-chemokine ligand 
CD Cluster of differentiation 
cDC Conventional type dendritric cell 
CDKN2A Cyclin dependent kinase inhibitor 2A 
cDNA Copy desoxyribonucleic acid 
CFSE 5-(6-)-Carboxyfluorescein diacetate succinimidyl ester 
CM Conditioned medium 
CMP Common myeloid progenitor  
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 
Cy7 Cyanine 7 
CXCL CXC-chemokine ligand 
DC Dendritic cell 
DMSO Dimethylsulfoxid 
DNA Desoxyribonucleic acid 
ECM Extracellular matrix 
EDTA Ethylendiamintetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence-activated cell sorting 
FAK1 Focal adhesion kinase 1 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FITC Fluorescein isothiocyanate 
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GM-CSF Granulocyte-macrophage colony-stimulating factor 
GMP Granulocyte macrophage progenitor 
G-CSF Granulocyte colony-stimulating factor 
G-MDSC Granulocytic MDSC 
HA Hyaluronic acid 
HNF1A Hepatocyte nuclear factor 1A 
HSC  Hematopoetic stem cell  
IDO1 Indoleamine 2,3-dioxygenase 1 
IFN Interferon 
IFNAR Interferon-alpha receptor 
Ig Immunglobulin 
IL Interleukin 
iNOS Inducible nitric oxide synthases 
IRF IFN regulatory factor  
ISRE IFN-stimulated response elements 
JMJD3 Jumonji domain containing protein D3 
KPC model Genetically engineered mouse model of pancreatic 
 cancer with krasG12D mutation and p53 inactivation 
KRAS Rat sarcoma (proto-oncogene) 
KRT81 Keratin 81 
LOX1 Lectin-type oxidized LDL receptor-1  
Ly6C Lymphocyte antigen 6 complex, locus C 
Ly6G Lymphocyte antigen 6 complex, locus G 
MACS Magnetic-activated cell sorting 
MAVS Mitochondrial antiviral-signaling protein 
M-MDSC Monocytic myeloid-derived suppressor cells 
MDA5 Melanoma differentiation-associated antigen 5 
MDSC Myeloid-derived suppressor cells 
MFI Mean fluorescence intensity 
MHC Major histocompatibility complex 
Min Minute(s) 
moDC Monocyte-derived DC 
mRNA Messenger RNA 
MSI Microsatellite instability 
Myd88 Myeloid differentiation primary response 88 
NK cell  Natural killer cell 
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NLR Neutrophil-to-lymphocyte ratio 
NOS Nitrogen species 
NOX Nicotinamide adenine dinucleotide phosphate oxidase 
OVA Ovalbumin 
PBS Phosphate-buffered saline 
PD-1 Programmed cell death protein 1 
PDAC Pancreatic ductal adenocarcinoma 
pDC Plasmacytoid DC 
PDCD1 Gene coding for PD-1 
PD-L1 Programmed cell death 1 ligand 1 
PE Phycoerythrin 
PerCP Peridinin-chlorophyll-protein complex 
Poly(I:C) Polyinosinic:polycytidylic acid 
PMN-MDSC Polymorphonuclear MDSC 
Prdm1 PR domain zinc finger protein 1 
PRR Pattern recognition receptor 
RIG-I Retinoic acid-inducible gene I 
RLH RIG-I-like helicases  
RNA Ribonucleic acid 
RNA-Seq RNA sequencing 
RORt RAR-related orphan receptor 
ROS Reactive oxygen 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
SEM Standard error of mean 
SMAD4 MAD-Homolog 4 
STAT3 Signal transducer and activator of transcription 3 
T110299 KPC-derived PDAC cell line 
TAM Tumor-associated macrophages 
TCR  T cell receptor 
TGF Transforming growth factor 
Th cell T helper cell 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TP53 Gene coding for protein 53 (tumor suppressor) 
Treg Regulatory T cell 
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